

Index

Hoffbrand's Essential Haematology 9E, 2024

Note: Page locators in **bold** indicate tables. Page locators in *italics* indicate figures. This index uses letter-by-letter alphabetization.

- AAV (adeno-associated virus) 377, 378, 379
- abciximab 433, 434
- abdominal disease, in non-Hodgkin lymphoma 266
- abdominal vein thrombosis 409
- ABL1 144
- ABL1 inhibitors 166, 189, **191**
- ABO blood group 56, 157, **157**, 404, 452–453, 453–458, **454**, 454, 457, 473
- absolute polycythaemia 198
- ABVD regimen, Hodgkin lymphoma 251, 253
- acalabrutinib 241
- acanthocyte 24, 442
- acanthocytosis 442, 443
- acerculoplasminaemia 43, 45
- acquired coagulation disorders 157, 385–398, **386**, **388**, 439–440, **440**, **442**, 442–443
- DIC *see* disseminated intravascular coagulation (DIC)
- acquired haemolytic anaemias 67, **67**, 74–77, 77, 397, 442, 443, 444
- microangiopathic *see* microangiopathic haemolytic anaemia (MAHA)
- acquired uniparental disomy (aUPD) 150
- acquired von Willebrand syndrome (AVWS) **386**, 387
- acrocyanosis 76
- acrolein 333
- actin, red cell membrane 20
- actin filaments, platelet cytoskeleton 341, 343–344
- activated partial thromboplastin time (APTT) 351–352, 351, **352**, **353**, 373, 392, 407, 408, 420, 428, 471
- activated protein C (APC) 348, 348, 403, 403
- acute blood loss 464
- acute hyperviscosity syndrome 282
- acute leukaemia 169–184, 222–235, **476**, **477**
- acute lymphoblastic leukaemia (ALL) 143, 145, **145**, **147**, 149, 150, 152, 153, 169, 169, 173, 177, 186, 187, 222–235, 223, **224**, 225, 226, **227**, 228, 230–232, 234
- acute myeloid leukaemia (AML) 143–144, **145**, 149, 152, **147**, **169**, 169, 170–184, **170**, 170, 173, 174, **175**, **176**, 176, 177, **178**, 179, 180, 181, 182, 183, 195, 200, 206, 211, 212, 212, 223, 312
- acute myocardial infarction 435
- acute phase proteins 448–449, **449**
- acute phase response 340, 391–392, 448–449, 449
- acute promyelocytic leukaemia (APML) 173, 174, **178**, 180
- acute sickle chest syndrome 91–92
- ADAMTS13 395, 396, 396, 397
- ADAMTS13 gene mutations 396
- adaptive immune response 100, 121, 125
- adeno-associated virus (AAV), gene therapy in haemophilia 377, 378, 379
- adenosine diphosphate (ADP) 432, 433
- adenosine triphosphate (ATP) 18, 432
- adhesion molecules 7–8
- adult T-cell leukaemia/lymphoma (ATLL) 141, 244–245, 285
- afibrinogenemia 383
- African iron overload **43**, 45
- African macroglobulinaemia 134–135
- African siderosis (iron overload) **43**, 45
- African trypanosomiasis 447–448, 448
- age/ageing 3, 4, 144, 219, 237, 404, 438
- see also* elderly
- ageing-related clonal haemopoiesis (ARCH) **214**, 219
- AIHA *see* autoimmune haemolytic anaemia (AIHA)
- AKT, activation 7
- ALAS gene mutation 40
- albumin 122, 294, 463, 464
- alcohol, thrombocytopenia due to 363
- alcohol-induced pain 247
- Alder-Reilly abnormality 106, 107
- alemtuzumab (anti-CD52) 75, 128, 166, 316, 325
- ALK-positive histiocytosis 113
- ALK-positive (anaplastic large cell) lymphoma 285
- alkylating agents 141, 162, **163**
- allergic reactions, non-haematolytic, after transfusion 461
- allogeneic stem cell transplantation 76, 89, 96, 103–104, 157, 177, **178**, 192, 206, 218, 229, 231, 232, 240, 243, 278, 297, 321, 322, 323, **323**, 323, 324, 325, 326, 327, 327–335, 335
- allogeneic transplantation, alloimmune haemolytic anaemia 76
- alloimmune haemolytic anaemias **67**, 76
- alloimmunization 95, 321, 328, 459, 462, 463, 471
- allopurinol 158, 159
- all-trans-retinoic acid (ATRA) **164**, 166, 180
- alpha2-antiplasmin **345**, 349, 349
- alpha2-macroglobulin 348
- alpha granules, platelets 342, 344, 364, 364
- α -haemoglobin stabilizing protein (AHSP) 85
- α -storage pool disease 364, 364
- alteplase 434–435
- Alzheimer's disease 219
- amasacrine **164**
- aminocaproic acid 158, 366
- δ -aminolaevulinic acid synthase (ALAS) 17, 29, 30
- amniotic, function 51
- amphotericin, liposomal 177
- amyloid 294, 302–308, **303**
- amyloid light chain (AL) amyloidosis *see* amyloidosis
- amyloidosis 290, 302–308, **303**, 305, 306
- systemic AL *see* systemic (primary) AL amyloidosis
- amyloid P 303–304
- anaemia 14, 15, 16, 16, 20–24, 22, **23**, 24, 25, 38, **38**, 39, 40, **39**, 45, **46**, 86, 157, 204–206, 213, 218, 238, 248, 266, 281, **289**, 290, 291, 291, 299, 314, 317–318, 318, 438, **440**, 441–446, **441**, **442**, **444**, 466, 466, 468–470, 472,
- anaemia of chronic disease (ACD) 28, 28, 36, 38–39, **38**, 39, **39**, 41, 438, **438**, **440**
- anagrelide, essential thrombocythaemia 204
- analgesia, sickle-cell disease 94
- anaphylactic reactions, blood transfusion reaction 461
- anaphylaxis 125
- anaplastic large cell lymphoma (ALCL) **267**, 284, 285
- andexanet alfa 428
- androgen therapy, in aplastic anaemia 316
- anencephaly 58
- aneuploid cell 145
- angioimmunoblastic lymphadenopathy 284
- angioimmunoblastic lymphoma 283–284
- angular cheilosis 34, 57, 57
- anisocytosis 24
- ankyrin 20, 20
- Ann-Arbor staging, Hodgkin's lymphoma 250, 251
- antenatal diagnosis 97, 97, 373
- anthracyclines **164**, 257
- anti-apoptotic proteins 9, 237
- anti-beta 2-glycoprotein-1 (anti- β 2-GP1) 407, **407**, 408
- antibiotics 161, 331–332
- antibodies 126, 128, 152, 166, 362, 362
- monoclonal *see* monoclonal antibodies
- see also* immunoglobulin(s); *specific antibodies/immunoglobulins*
- antibody-dependent cell-mediated cytotoxicity (ADCC) 121
- anticardiolipin antibodies 407, **407**, 408, 441
- anti-CD20 antibodies 166, 241, 242, 277
- anti-CD22 antibody-cytotoxic drug conjugate 233
- anti-CD30 antibodies 166, 253
- anti-CD38 antibodies 296, 297
- see also* daratumumab (anti-CD38)
- anti-CD52 (alemtuzumab) 75, 128, 166, 316, 325
- anti-CD138 291
- anticoagulants 157, **345**, 347–348, 348, 350, 403, 406, 418–420, 418, 419, **420**, **421**, 422, 423, 426–432
- anticoagulation 393, 395, 418, 423, 430–432
- anti-D immunoglobulin 76, 361, 453, 455, 471, 472

- anti-emetic therapy 158
 antifibrinolytics 376, 376
 see also tranexamic acid
 antifolate drugs 63
 antifungal agents 110, 162, 177, 331
 antigen presentation 112, 125, 125, 133, 325–326
 antigen-presenting cells (APC) 125, 125
 antigen processing 125
 antigen receptor 118, 119
 antigen–receptor gene rearrangements 122, 123, 149
 immunoglobulin gene *see under*
 immunoglobulin(s)
 antigen recognition 119, 125, 125
 antiglobulin (Coombs') test 458, 458, 459
 antihuman globulin (AHG) 458
 anti-K 469
 anti-lymphocyte globulin (ALG, ATG) 315,
 316, 325
 antimetabolic drugs 63, **163–164**, 165, 178, **178**
 antimicrobial agents 110, 160–162, 177, 331–332
 antiphospholipid antibodies (aPL) 407, 408
 antiphospholipid syndrome (APS) 407, **407**,
 428, 430, 432
 α2-antiplasmin **345**, 349, 349
 antiplasmin/plasmin system 348, 349, 349
 antiplatelet drugs 157, 365, **366**, 418, 432–434,
 433, 435
 antiseptics, for bathing 160, 331
 antithrombin (AT) **345**, 347, 348, 348, 377, 378,
 403, 418, 419, 419, 471
 antithrombin (AT) concentrates 157
 antithrombotics 418, 434–435
 see also anticoagulants; antiplatelet drugs
 anti-thymocyte globulin (ATG) 315, 316, 325
 antiviral drugs 331
 anti-Xa assay 420, 422
 aorta–gonads–mesonephros (AGM) region 2
 APAF-1 9
 apixaban 418, 423, 427, **427**, **429**
 aplastic anaemia 26, 104, 310–311, 310, **311**, 312,
 313–316, **315**, 316, 324, 326, 333, 442,
 442, 443
 aplastic crises 67, 70, 92
 APLM *see* acute promyelocytic leukaemia (APML)
 apoptosis 5, 9, 9–10, 127, 143, 144, 211, 237
 apparent (pseudopolycythaemia) polycythaemia 20,
 198, 202
 APS *see* antiphospholipid syndrome (APS)
 APSAC 435
 APTT *see* activated partial thromboplastin time
 (APTT)
 arachidonic acid 432, 433
 argatroban 422
 L-arginine 105
 arsenic 166
 arsenic trioxide (ATO) **164**, 180
 arterial (white) thrombi 400, 432
 arterial thrombosis 414–415, **415**, 418, **421**, 422,
 435, 438
 arteriovenous malformations 77, 368
 arthropathy, in haemophilia 372, 373
 asciminib 166, 190, **191**
 Ashwell–Morell receptor 340, 341
 asialoglycoprotein receptor (ASGPR) 340
 asparaginase 157, 166
 aspergillosis, invasive 161–162
Aspergillus fumigatus 161, 161–162
 aspirin 95, 200–201, 432, 433, 435
 asplenia, vaccination schedule 136, **137**
ASXL1 gene mutations 197, 314
 atheroemboli, warfarin associated 424
 atherosclerosis 414, **415**, 435
 atherosclerotic plaque 414
ATM mutation, chronic lymphocytic
 leukaemia 239–240
 ATR-16 syndrome 84
 ATRA (all-trans-retinoic acid) **164**, 166, 180
 ATRA syndrome 180
 atrial fibrillation (AF) 415, 418, 422, 426
ATRX gene mutation 84
 atypical chronic myeloid leukaemia (aCML) 220
 Auer rods 174
 autoantibodies/autoimmunity 75, 359, 360
 autoimmune diseases 54–55, **263**, 333, **366**, 443
 autoimmune haemolytic anaemia (AIHA) **67**,
 74–76, **74**, 75, 238, 239, 440, 442, 443
 autoimmune lymphoproliferative syndrome
 (ALPS) 129
 autoimmune neutropenia 109, **109**
 autologous stem cell transplantation 89, 103–104,
 272, 296, 297, 306, 321, 322, **323**, 323, 325,
 327, 328
 automated blood cell counter 13
 autophagy 10
 avascular necrosis of bone 91, 92
 avatrombopag 361
 AVD-BV regimen 253–254
 AVD regimen, Hodgkin lymphoma 253
 axillary venous thrombosis 409
 azacytidine **164**, 166, **178**, 179, 219
 azurophilic granules 244, 245
 babesiosis 77
 bacteria 105, 105, 453
 bacterial infections 142, 160–161, **263**, 330–331,
 331, 333, 443, **456**, 457
 B-ALL *see under* acute lymphoblastic
 leukaemia (ALL)
 bancroftian filariasis 448, 449
 Barr body 105, 107
 bartonellosis 443
 basket cell 24
 basophil(s) **3**, **12**, 100, 102
 basophil count **12**, **21**, **100**, 111, 186, 188
 basophilic stippling, red cells 25, 41
 basophil leucocytosis (basophilia) 111, 186, 188
 BAX 9
 B cell(s) *see* B lymphocytes
 B-cell acute lymphoblastic leukaemia *see* acute
 lymphoblastic leukaemia (ALL)
 B-cell lymphoma 247, 249, **250**, 257, 260
 large *see* large B-cell lymphoma
 B-cell lymphoproliferative disorder, age-related 237
 B-cell maturation antigen (BCMA) 121
 B-cell neoplasms 118, 129, 152, 223, 224, **224**, 237,
 237, 243–244, **261**, 264
 B-cell non-Hodgkin lymphoma (NHL) 260, 260,
 261, 262, 262, **263**, 264, **265**, **266**, 267, **269**,
 271–281
 see also non-Hodgkin lymphoma (NHL); *specific*
 lymphomas
 B-cell prolymphocytic leukaemia (B-PLL) 243
 B-cell receptor (BCR) 118, 119, 125, 241
 BCL-2 9, 9, 237, 241, 277
BCL2 gene 9, 143, 149, 149, **267**, 271, 273, 276,
 277
 BCL-2 inhibitor 9, 206, 241, 242, 242
 see also venetoclax
 BCL6 **266**, 271, 277
BCL6 gene, large B-cell lymphoma 271
 BCL11A, actions 81
BCL11A gene 86, 89, 90, 96
 BCOR gene mutation 314
BCORL1 gene mutation 314
 BCR::ABL1 fusion protein 166, 172, 186, 187
BCR::ABL1 gene rearrangement 186, 187, 223, 224,
 227, 230, 233, 234, 334
 BEACOPP regimen, Hodgkin lymphoma 253, 254
 BEAM regimen 325
 Bence–Jones protein 122, 291, 294
 bendamustine 76, 162, **163**, 241
 benign monoclonal gammopathy *see* monoclonal
 gammopathy of undetermined significance
 (MGUS)
 Bernard–Soulier syndrome (BSS) 343, 365, 365
 β2-GP1 407, **407**, 408
 'big spleen disease' 134–135
 bilirubin 24, 66, 67
 bilirubin gallstones 67, 68, 69–70
 bilirubin glucuronides 66
 biliverdin 66
 Binet staging system 240, **240**, 241
 Birbeck granules 111–112
 birefringence, in amyloidosis 305, 305
 birtamimab, systemic AL amyloidosis 306
 bi-specific antibodies, in relapsed DLBCL 273
 bi-specific T-cell engager (blinatumomab) 231,
 233, 233
 bisphosphonates 298
 'bite' cells 72, 73
 bivalirudin 422
 blackwater fever 77, 447
 blast cells 169, 169, 170, 170, 172, 174, **175**,
 186, 188–189, **189**, 189, **211**, 213, 223,
 226, 226
 blastic plasmacytoid dendritic cell neoplasm
 (BPDCN) 172
 bleeding 206, 290, 299, 312, 338, 350–353,
 356–357, **357**, **358**, 359, 360, 372, 372, 379,
 381–382, 391, 422, 424, **425**, 426, 428
 see also blood loss; haemorrhage
 bleeding disorders 355–369, 382–384, 439, 440,
 441, 442, **442**
 bleeding tendency 172, 356, **357**, 387, 442, **442**
 bleomycin **164**, 166
 blinatumomab 231, 233, 233
 'blister' cells 72, 73
 blood cells 12, **12**, **21**
 see also specific cell types
 blood clot 338, 338, 339, 344, **345**, 347–349, 390,
 390, 400, 418, 434–435
 see also coagulation; thrombosis
 blood count 13, **21**, **100**, 350, 359, 365, **469**
 blood disorders, venous thromboembolism
 risk 406
 blood film 23, 24, 25, 28, 35, 35, 59, 59–60, 70, 70,
 73, 75, 75, 94, 85, 87, 107, **108**, 108, 111,
 172, 174, 186, 188, 189, 203, 203, 213–214,
 216, 226, 226, 238, 238, 243, 244, 266, 266,
 284, 293, 350, 365, 408, 443, 445, 460,
 468, 473,
 blood flow, laminar, and turbulence 400
 blood group(s) 452–458, **454**, 457, 457–458, 458
 blood group antibodies 76, 452–453, 455,
 471, 472
 blood loss 20, 23, 33, **34**, 36, 37, 464, 467
 see also bleeding; haemorrhage
 blood transfusion 75–76, 86, 87, 94, 95, 157, 218,
 251, 332–333, 362, 363, 392, 451–464, 452,
 453, **456**, 457, **458**, 458, **459**, **460**, 460, **461**,
 461, 463, 469, 470, 473
 blood vessels, blood flow and wall damage 400
 blood volume, major blood loss 20

- Bloom syndrome 141
 B lymphocytes (B cells) 3, 3, 12, 117–118, **118**, 119, 121, 122, 122, 123, 125, 125, 127, 129, 132, 132, 133, 143, 237, 238, 240, 241, 262, 264, 294, 334, 360
 BMP2 30
 BMP6 30
 BNLI criteria, non-Hodgkin lymphoma treatment **269**
 bone 86, 86, **289**, 290, 298, 318
 bone marrow 2–4, 2–5, 14, 23–24, **25**, 25, 26, 35, 36, 41, 60, 60, 67, 68, 102, 110, 112, 113, 114, 117, 118, 128, 140, 141, **147**, 156, 172, 174, 186, 195, 198, **199**, 200, 203, 204, 205, 206, 211, 213–215, 216, 225, 226, 226, 239, 239, 288–290, **289**, 290, 299, 309–319, **311**, 312, 317, 318, 321, 325, 339, **358**, 359, 363, 438, 439, 446, 446
 bone marrow transplantation (BMT) 321, 323
 see also stem cell transplantation (SCT)
 bone morphogenetic proteins (BMP) 30, 31
 bone pain 159, 290
 bortezomib 76, 166, 298, 305, 306
 bosutinib 189, **191**
 brachial vein, thrombosis 409
BRAF gene, V600E mutation 112, 243
 brain damage, sickle cell disease 92
 brain natriuretic peptide (BNP) 305
 breast carcinoma 108, 438, 439
 brentuximab 166, 253
 brentuximab vedotin (BV) 253
 Broviac-style catheter 156
 bruising 113, 220, 368
 see also ecchymoses
 Bruton tyrosine kinase (BTK) 118, 119, 129, 144, 241
 Bruton tyrosine kinase inhibitors (BTKi) 119, 166, 241–243, 279, 281–282
 B-symptoms 247, 265
 Budd–Chiari syndrome 200, 203, 409
 buffy coats 188, 452, 462–463
 Burkitt lymphoma 143, **145**, 149, 150, 264, 264, **266**, **267**, 275–276, 276, 446
 ‘burr’ cells (echinocytes) 24, 441, 441
 burst-forming units (BFU) 2–3, 3, 12, 16
 busulphan **163**, 324
 bypass therapies, in haemophilia 375–376

 C4b-binding protein (C4bBP) 403
 C282Y mutation 44
 cadherins 7
 CAEL101 306
 caeruloplasmin 28
 calf veins, thrombosis 408, 409
 CALR (calreticulin) 195, 196
CALR gene mutation 144, 195, 196, 197, 202, **202**, 204, 206
 cancer *see* malignant disease
 cancer-associated thrombosis (CAT) 406, 428, 432
Candida infections 161, 162, 173
 cangrelor 432–433, 434
 caplacizumab 397
 cardiac damage, transfusional iron overload 46
 cardiac failure 142, 333
 cardiac haemolysis 77
 cardiac T_2^* MRI 47, 47, 49
 cardioliipin 407
 cardiopulmonary bypass, platelet disorders **366**
 carfilzomib 166, 296, 297, 298
 CAR-NK cells 121
 carotid artery thrombi 414
 CAR-T cells *see* chimeric antigen receptor T cells (CAR-T)
 casein kinase 1 218
 caspases 9
 Castleman disease 285, 446
 catheter-directed thrombolysis (CDT) 430
CCND1 gene 279
 CD2 207
 CD3 125
 CD4 119, 125
 CD4 T lymphocytes (helper T cells) 119, 125, 125, 325–326, 360
 CD5, in B-cell lymphomas **266**
 CD7 224
 CD8 T lymphocytes 119, 125, 325
 CD10 **266**, 277
 CD15 248
 CD19 121, 167, 231, 233, 238, 242
 CD20 121, **266**, 277
 CD21 262, 277
 CD22, antibodies 233
 CD23, B-cell lymphomas **266**
 CD25 207
 CD30 166, 207, 248, 253, 255, 285
 CD33, antibodies to 178
 CD34 2, 169, 321
 CD34⁺ stem cells, selection, transplantation 321, 323
 CD38 2, 296, 297
 CD39 350
 CD41 (GPIIb) 365
 CD45RA 2
 CD49f 2
 CD52, antibodies (alemtuzumab) 75, 128, 166, 316, 325
 CD55 (decay accelerating factor) 124, 316
 CD59 (membrane inhibitor of reactive lysis) 124, 316
 CD61 (GPIIIa) 365
 CD71 16
 CD90 2
 CD117 (KIT) 4
 CD138 289, 291
 CD207 112
CDAN1 (codanin) gene 318
CEBPA gene mutation 171
 cell adhesion molecules (CAMs) 7–8
 cell cycle 8
 cell cycle checkpoints 8, **165**, 166
 cell salvage, intraoperative 462
 central nervous system *see* CNS involvement
 central retinal vein occlusion 409
 central venous catheter, insertion 156, 156–157
 centroblasts 125
 centrocetes 125, 127
 centromeres 145, 148
 cerebral ischemia 414
 cerebral vein thrombosis 428
 cerebral venous and sinus thrombosis (CVST) 408–409
 cerebrospinal fluid (CSF) 226, 231
 cervical lymphadenopathy 126, 225, 225, 238, 238, 247, 247
 Chagas’ disease 457
 checkpoints, cell cycle *see* cell cycle checkpoints
 Chédiak–Higashi syndrome 107, 107
 cheilosis, angular 34, 57, 57
 chemicals, diseases due to 141, 314
 chemo-immunotherapy, chronic lymphocytic leukaemia 241–242
 chemokines 102, 105
 chemotaxis 105, 106
 chemotherapy 103–104, 158, 159, 180, 219, 251, 253, 254, 256, 257, 296–297, 305–306, 323–324, 406
 see also cytotoxic drugs
 ‘cherry-red’ spot 115
 chest pain, pulmonary embolism 412
 chest X-ray 37, 92, 156, 161, 162, 225, 248, 268, 275, 412
 children 183, 213, 359, 428, 468
 ALL *see* acute lymphoblastic leukaemia (ALL)
 see also infants
 chimeric antigen receptors 166
 chimeric antigen receptor T cells (CAR-T) 119–121, 120, 128, 129, **165**, 166–167, 233, 242, 255, 272, 278, 279, 284–285, 321
 chimeric fusion gene 149, 149
 chimerism 328
 chimerism analysis 328
Chlamydia psittaci **263**
Chlamydia trachomatis 142
 chlorambucil 162, **163**, 241
 chloramphenicol 314
 ‘chloroma’ 172
 CHOEP regimen 284
 cholecystectomy 71
 cholesterol microemboli 424
 chondroitin sulfate 419
 CHP regimen, large B-cell lymphomas 271
 Christmas disease *see* haemophilia B (FIX deficiency)
 chromatin 9
 chromosomal abnormalities 197, 197, 223–224, 239–240, 311
 chromosomal deletion/loss 148, 149, 197, 239, 241
 chromosomal duplication/amplification 148, 150, 248–249
 chromosomal inversions 149–150
 chromosomal translocations 9–10, 143, **147**, 148, 149, 149, 149–150, 150, 151, 152, 173, 176, 186, 223, 224, 227, 233, **267**, 271, 273, 275, 276, 279, 288, 294, 304
 chromosome(s) 145, 147–148, 147, 148
 chronic eosinophilic leukaemia 111, 208
 chronic granulomatous disease 106–107
 chronic lymphocytic leukaemia(s) **237**, 237–245
 chronic lymphocytic leukaemia (CLL) 141, **145**, **147**, 150, 151, 236–245, **237**, 238, **239**, 239, **240**, 241, 242, **243**, 260, **267**
 chronic myeloid leukaemia (CML) **145**, 185–193, 187, 188, **189**, 189, 190, 191, **191–193**, **196**, 333–334, 334
 chronic myelomonocytic leukaemia (CMML) 220, **220**
 chronic neutrophilic leukaemia 207–208
 chronic thromboembolic pulmonary hypertension 414
CHS1 (*LYST*) gene mutations 107
 Churg–Strauss syndrome 111
 ciclosporin 243, 315, 325
 cilostazol 433, 434
 circulating neoplastic DNA 152
 cladribine **164**, 244
 Clauss fibrinogen assay 352
 clinical prediction rules 409–412, **410**, **412**
 CLL *see* chronic lymphocytic leukaemia (CLL)
 CLL International Prognostic Index (CLL-IPI) 240, **241**
 clofarabine **164**
 clonal cytopenia of undetermined significance (CCUS) 109, **214**, 219
 clonal diseases/abnormalities 3, 140, 141, 144, **147**, 195, 198, 223, 223
 see also specific haematological malignancies

- clonal haemopoiesis **214**, 219
clonal haemopoiesis of indeterminate potential (CHIP) **144**, **147**, **214**, 219, 415
clonal progression, haematological neoplasia **3**, 144, **146**, **147**
clopidogrel **432–433**, **433**, **434**
Clostridium perfringens **77**, **443**, **444**
clot, blood *see* blood clot
clotting factor concentrates (CFCs) **374**, **374**
clotting time **351**, **352**, **352**
‘clover leaf’ lymphocytes **244**, **245**
CML *see* chronic myeloid leukaemia (CML)
CMML (chronic myelomonocytic leukaemia) **220**, **220**
CMV *see* cytomegalovirus (CMV) infection
CNS involvement **226**, **231**, **272**, **274**
coagulation **338**, **345–348**, **346**, **348**, **350–352**, **352**, **356**, **390**, **391**
coagulation disorders **350–351**, **352**, **468**, **471**
 acquired *see* acquired coagulation disorders
 inherited *see* inherited coagulation disorders
coagulation factors/proteins **344**, **345**, **346**, **346**, **374**, **374**, **375**, **386**, **386**, **387**
 see also specific factors beginning ‘Factor’
coagulopathies, consumptive **358**
coagulopathy of critical illness **391–392**
cobalamins **51**
cold agglutinin disease **74**, **76**
cold agglutinins **76**, **122**
cold antibodies **67**, **128**, **453**
cold autoimmune haemolytic anaemia **74**, **75**, **76**, **443**
collagen, hereditary abnormalities **368**
colon carcinoma **37**, **438**, **439**
colonoscopy, virtual, iron deficiency and **37**, **37**
colony-forming unit (CFU) **2–3**, **3**, **12**, **16**
colony-stimulating factor 3 receptor (*CSF3R*) gene, mutation **208**
combined modality treatment (CMT), Hodgkin lymphoma **251**, **253**
compensated haemolytic disease **67**
complement **74**, **76**, **124–125**, **124**, **316**, **317**
complement-mediated haemolytic uraemic syndrome (CM-HUS) **398**
compression stockings/devices **414**, **430**, **432**
computed tomography (CT) **129**, **133**, **134**, **134**, **161**, **162**, **248**, **250**, **292**, **412**
 see also positron emission tomography/computed tomography (PET/CT)
computed tomography pulmonary angiography (CTPA) **411**, **413**
congenital afibrinogenemia **404**
congenital dyserythropoietic anaemias (CDA) **318**
congenital fibrinogen disorders (CFDs) **383**
congenital primary polycythaemia **198**, **202**
congestive heart failure (CHF) **142**
Congo red stain **304**, **305**, **305**
conjunctival mucosa, pallor, in anaemia **22**, **22**
connective tissue disorders **368**, **440–441**
contrast venography, DVT investigation **411**, **412**
Coombs’ test *see* antiglobulin (Coombs’) test
cord blood *see* umbilical cord blood
core biopsy, non-Hodgkin lymphoma **264**
coronavirus infection **161**
 see also COVID-19 (SARS-CoV-2) infection
corticosteroids **75**, **110**, **164**, **166**, **242**, **315**, **361**
Cosmofer **38**
coumarins **420**
Council of Europe, blood transfusion code **452**
COVID-19 (SARS-CoV-2) infection **392–395**, **444–445**, **445**
COX-1 inhibition **432**, **433**
CpG islands **143**
CRAB acronym **289**, **290**
cranial nerve palsy **225**
C-reactive protein (CRP) **304**, **438**, **448–449**, **449**
creatinine, serum, raised in myeloma **291**
Creutzfeldt–Jakob disease, new variant (nvCJD) **456**, **457**, **462**
CRISPR/Cas9 gene editing **89**
crizanlizumab **95**
crizotinib **166**
CRLF2 gene **224**
CRP (C-reactive protein) **304**, **438**, **448–449**, **449**
cryoglobulin **280**
cryoprecipitate **157**, **374**, **452**, **464**
‘cryptogenic splenomegaly’ **134–135**
CSF3R gene mutation **208**
CT *see* computed tomography (CT)
cubam **51**
cubilin **51**
CXCR4 **4**, **321**
CXCR4 gene mutation **281**
CyBorD regimen **305–306**
cyclic AMP (cAMP) **344**
cyclin D1 gene **279**, **288**
cyclin D2 gene **288**
cyclin D3 gene **288**
cyclin-dependent protein kinases (Cdk) **8**
cyclins, actions **8**
cyclo-oxygenase (COX) **344**, **432**
cyclophosphamide **162**, **163**, **241**, **324**, **325**
cystathionine beta-synthase (CBS) deficiency **404**
cystitis, haemorrhagic **333**
cytarabine **164**, **165**
cytochrome c **9**
cytogenetics *see specific diseases*
cytokine(s) **6**, **30**, **39**, **167**, **448**
cytokine release syndrome (CRS) **167**
‘cytokine storm’ **112**
cytomegalovirus (CMV) infection **126**, **157**, **161**, **331–332**, **332**, **443**, **456–457**, **462**, **463**
cytopenia **211**, **213**, **215**, **217**, **219**, **244**, **266**
 see also pancytopenia; *specific cell types*
cytosines, methylated, deamination **143**
cytotoxic antibiotics **164**, **165–166**
cytotoxic drugs **162**, **163–165**, **165–166**, **172**, **178**, **178**, **314**
cytotoxic T cells (CD8⁺) **9**, **119**, **119**, **125**, **325**, **360**
dabigatran **418**, **422**, **423**, **427**, **428**, **429**, **432**
dactylitis **91**, **93**
dalteparin **421**, **432**
damage-associated molecular patterns (DAMPs) **390**
danaparoid **422**
danazol **316**
daprodustat **15–16**, **442**
daratumumab (anti-CD38) **233**, **296–298**, **305–306**
Dara-VRd therapy, multiple myeloma **296**
darbepoetin **16**, **442**
DARC/DARC gene **102**
dasatinib **166**, **189**, **191**
D-dimers **347**, **349**, **352–353**, **359**, **409**, **411**, **413**
Deauville scoring system **251**, **264**
decay-activating factor (DAF) **316**
decitabine **164**, **166**, **178**, **179**, **219**
deep vein thrombosis (DVT) **395**, **400**, **401**, **405**, **406**, **408**, **409**, **410**, **410**, **411**, **411–414**, **414**, **418**, **423**, **430–432**, **431**, **435**
 see also venous thrombosis
deferasirox **48**, **48**, **87**, **95**
deferiprone **48**, **48**, **87**, **95**
deferroxamine **48**, **48**, **87**, **95**
δ-storage pool disease (δ-SPD) **364**
demarcation membrane system (DMS) **339**
demethylation agents **150**, **164**, **166**
dendritic cell(s) (DC) **111–112**, **111**, **125**, **133**, **285**, **476**
dendritic cell disorders **111**, **111–113**
dense granules, platelets **342**, **344**
dense tubular system (DTS), platelets **342**
denusomab **298**
deoxyhaemoglobin **17**
dermatan sulfate **419**
desmopressin (1-diamino-8-D-arginine vasopressin, DDAVP) **366**, **367**, **375**, **381**
developing countries, iron deficiency **34**, **35**
dexamethasone **75**
Diafer **38**
Diamond–Blackfan anaemia (DBA) **317–318**, **318**
DIC *see* disseminated intravascular coagulation (DIC)
differentiation syndrome **180**
diffuse large B-cell lymphomas (DLBCL) **243**, **260**, **264**, **266**, **266**, **267**, **268**, **271–275**, **271**, **272**, **273**, **273**, **274**, **334**
dihydrofolate (DHF) **53**
dihydrofolate reductase **53–54**
2,3-diphosphoglycerate (2,3-DPG) **17**, **18**, **21**, **73**, **441**
diploid cell **145**
dipyridamole **433**, **434**
direct-acting oral anticoagulants (DOACs) **415**, **419**, **420**, **422**, **426–430**, **427**, **429**
direct antiglobulin (Coombs’) test (DAT) **70**, **74–76**, **124**, **458**, **473**
direct oral anticoagulants (DOAC) *see* direct-acting oral anticoagulants (DOACs)
direct thrombin inhibitors **422**
disseminated intravascular coagulation (DIC) **77**, **172**, **352**, **363**, **389–391**, **389**, **390–392**, **439**, **443**, **459**
divalent metal transporter 1 (DMT1) **29**, **30**, **32**, **33**
DMT1 gene mutations **39**
DNA **8–9**, **51**, **51**, **53**, **63**, **148**, **150**, **152**, **165**, **212**, **373**
DNA alkylating agents **141**
DNA hypomethylating agents **178**, **179**
DNA methyltransferase genes **9**
DNMT3A **212**
DNMT3A gene **150**, **170**, **197**, **212**
DOAC *see* direct-acting oral anticoagulants (DOACs)
Döhle bodies **106**, **107**, **443**, **445**
Donath–Landsteiner antibody **76**
donor leucocyte infusions (DLI) **324**, **333–334**, **334**, **335**
Doppler ultrasound **92**, **93**, **411**, **411**, **472**, **473**
double expressor lymphomas **271**, **273**
double hit lymphoma **271**, **272**, **273**, **274**
Down syndrome **141**, **172**, **223**
DRd therapy, multiple myeloma **297**
driver mutations **143–144**, **170**, **195**, **196**, **197**, **204**, **212**
 see also gene mutations; *specific disorders*
drug(s) **72**, **73**, **76–77**, **109**, **109**, **141**, **163–165**, **356**, **362**, **362**, **363**, **365**, **366**, **366**, **424**, **428**, **439**
drug-induced immune haemolytic anaemias **72**, **73**, **76–77**
drug-induced immune thrombocytopenia **356**, **362**, **362**, **363**
Duffy antigen chemokine receptor gene (*DARC*) **102**

- duplex ultrasound, DVT investigation 411, 411
DUSP22 gene 285
 dyserythropoiesis 337, 446
 dysfibrinogenemia 383, 404, 443
 dyskeratosis congenita (DKC) 148, 311, 312–313
- E2F transcription factor 8
 early T-precursor (ETP) ALL 224
 Eastern Cooperative Oncology Group (ECOG) 156, 156
 ecchymoses 356, 357, 359
 see also bruising
 echinocytes ('burr' cells) 24, 441, 441
 echinocytosis 442, 443
 echocardiography 413
 eculizumab 76, 95, 317
 edoxaban 418, 423, 427, 427, 429
 EDTA (ethylenediaminetetraacetic acid) 350, 358
 Ehlers–Danlos syndrome 368
 eIF2 α kinase 17
ELANE2 gene mutations 109
 elderly 21, 144, 171, 182, 183, 438
 see also age/ageing
 electrocardiography (ECG), pulmonary embolism 412–413
 eliglustat 115
 elliptocyte 24
 elotuzumab, multiple myeloma 298
 eltrombopag 218, 315, 361
 Embden–Meyerhof pathway 18–19, 19, 73
 embryonic yolk sac 2
 emicizumab 376, 377, 386
 enasidenib 164, 166
 encephalocele 58
 endocrine complications, stem cell transplant 333
 endocrine therapy, in β -thalassaemia major 87
 endomitosis 339, 339
 endothelial cell(s)/endothelium 102, 339, 343, 344, 349, 350, 368, 390, 390, 393, 400
 endothelial cell protein C receptor (EPCR) 348, 348
 enoxaparin sodium 421, 432
 enteropathy-associated T-cell lymphomas (EATL) 284, 285
 enzyme replacement therapy (ERT), glucocerebrosidase, Gaucher disease 113, 115
 EORTC criteria, Hodgkin lymphoma (HL) 253
 eosin-5-maleimide (EMA) 70, 71
 eosinophil(s) 3, 12, 21, 100, 100, 102, 208
 eosinophilic leucocytosis (eosinophilia) 110–111, 111, 111, 208
 epcoritamab 273
 epigenetic alterations 8–9, 148, 150, 212
 epigenetic modifiers 164
 epigenetic therapy, acute myeloid leukaemia 178
 epistaxis 357, 368
 epoetin 442
 Epstein–Barr virus (EBV) 126, 128, 141–142, 161, 247, 262, 263, 275, 334, 335
 eptifibatide 433, 434
 Erdheim–Chester disease (ECD) 113
 Erlenmeyer flask deformity 113, 114
 erythroblastic activity, normal and in anaemia 24, 26
 erythroblasts (normoblasts) 12, 13, 14, 14, 24, 25, 30, 51, 60, 215, 216
 erythrocyte(s) *see* red blood cells (RBC)
 erythrocyte sedimentation rate (ESR) 248, 291, 438, 448, 449
 erythrocytosis 195, 198, 198
 see also polycythemia vera (PV)
 erythroferrone 30
 erythroid and megakaryocyte colony-forming unit (CFU_{MK}) 12
 erythroid colony forming unit (CFU-E) 3, 12, 16
 erythroid dysplasia, myelodysplastic syndromes 212, 215
 erythroid hyperplasia 26
 erythroid hypoplasia 26
 erythroid niche 12
 erythroid series progenitor 2–3, 12
 erythromelalgia 203
 erythropoiesis 2, 12–14, 14, 16, 24–26, 26, 29, 30, 318, 469
 erythropoiesis-stimulating agents (ESA) 157, 217, 438
 erythropoietin (EPO) 5, 6, 14–16, 15, 16, 16, 23, 438, 442, 462
 erythropoietin receptor gene (*EPOR*), mutation 202
Escherichia coli, Shiga-toxin-secreting 397
 ESR *see* erythrocyte sedimentation rate (ESR)
 essential thrombocythemia (ET) 195–197, 195, 196, 197, 202–204, 202, 203, 203
 etoposide 141, 164, 166
 ETV6::RUNX1 fusion protein 227
 ETV6::RUNX1 translocation 147, 151, 223, 224, 227, 233
 European Leukaemia Network (ELN) 477
 Evans' syndrome 74
 exchange transfusion 95, 473
 extramedullary haemopoiesis 2, 133
 extramedullary leukaemia 172
 extranodal marginal zone lymphoma of MALT type 280
 extranodal NK/T-cell lymphoma 284, 285, 285
 extravascular haemolysis 66, 66, 68
 extrinsic pathway, coagulation 346, 350–351, 351
EZH2 gene mutations 212
- F8* gene *see* under factor VIII (FVIII)
F9 gene *see* under factor IX (FIX)
 Fab fragment 119, 122
 facial asymmetry 225
 facial plethora 199, 199
 factor II *see* prothrombin (FII)
 factor IIa *see* thrombin (factor IIa)
 factor V (FV) 345, 383–384, 402, 403
 factor Va (FVa) 347, 348, 348, 402, 403, 403
 factor V Leiden (FVL) gene mutation 402–403, 403
 factor VII (FVII) 345, 383
 factor VIIa (FVIIa) 346, 367, 376
 factor VIII (FVIII) 343, 345, 371, 373–377, 374, 378, 379, 386, 386–387, 400, 404, 464
 factor VIIIa (FVIIIa) 348, 348, 403
 factor IX (FIX) 345, 371, 373–375, 374, 377, 378, 379, 464
 factor IXa (FIXa) 346, 346, 347
 factor IX (FIX) Padua 379
 factor X (FX) 345, 346, 346, 383
 factor Xa (FXa) 345, 346, 346, 347, 419, 419, 420, 421
 factor XI (FXI) 345, 383
 factor XII (FXII) 345, 347
 factor XIII (FXIII) 345, 383
 familial amyloidotic neuropathy 308
FANCD1 gene 311
 Fanconi anaemia (FA) 311, 311–312, 311, 313
 Fas pathway, apoptosis 9, 9
 fava beans 72, 73
 Fc fragment 119, 122
 Fc receptor, neonatal (FcRn) 122
 FCR regimen, chronic lymphocytic leukaemia 241
 Fc γ RIIa 343
 FDG-PET 129, 243, 248, 250, 252, 275
 Feltz syndrome 440, 441
 femoral artery 411
 femoral vein 409
 femoral venogram 411
 Feraheme 38
 Ferinject 38
 ferric carboxymaltose 38
 ferric hydroxide–sucrose 38
 ferric isomaltoside 38
 Ferriecit 38
 ferrioxidase 32, 33
 ferrireductase 32, 33
 Ferriscan MRI technique 43, 44, 47
 ferritin 21, 28, 29, 30, 33, 35, 36, 36, 43–45, 49, 442, 466
 ferroportin 30, 32, 33, 45
 ferrous fumarate 37
 ferrous salts, in pregnancy 466
 ferrous sulphate 37
 fertility preservation 158–159, 251, 255–256
 ferumoxytol 38
 fever 160, 161, 247, 265, 461
 FFP *see* fresh frozen plasma (FFP)
 fibrin 344, 347, 347
 fibrin meshwork 347, 347
 fibrinogen (FGN) 344, 345, 347, 347, 351, 352, 352, 383, 390–392, 404–406, 443, 464
 fibrinolysis 338, 345, 348–349, 349, 352–353, 356, 384, 387, 390, 391, 391
 fibrinolytic therapy 434–435
 see also thrombolytic therapy
 fibrinopeptides 347
 Fibroscan 44
 fibrosis, reactive 195, 204
 filgrastim 103
 fine needle aspiration 264
 FISH *see* fluorescence *in situ* hybridization (FISH) analysis
 FLAG-IDA 178
 FLIPI-1/FLIPI-2 (follicular lymphoma prognostic indices) 277, 278
 flow cytometry 151, 151–152, 153, 175, 227, 228, 231, 265, 352
FLT3 gene 143, 149, 150, 152, 166, 170, 175, 178, 181, 182
FLT3 inhibitors 144, 166, 178, 178
FLT3 kinase, inhibitors 144, 166
FLT3 ligand (*FLT3-L*) 6, 7
 fludarabine 164, 165, 241, 324
 fluid replacement 463
 fluorescence-activated cell sorting (FACS) 151, 151, 152
 fluorescence *in situ* hybridization (FISH) analysis 150, 151, 152, 153, 186, 188, 195, 204, 227, 265, 294, 328
 focussed abdominal ultrasound for trauma (FAST) 133, 133
 foetal blood groups 459, 471
 foetal bone marrow, mutations 147
 foetal haemoglobin *see* haemoglobin F (Hb F)
 foetal haemopoiesis 2, 2
 foetal loss 468
 foetal-neonatal alloimmune thrombocytopenia (FNAIT) 471
 foetal warfarin syndrome 424
 foeto-maternal haemorrhage 472
 FOG1 5, 16
 folate 21, 52, 53–54, 54, 55, 56, 56, 61, 63, 467
 see also folic (pteroylglutamic) acid
 folate antagonists 165

- folate deficiency 35, 40, 56, **57**, 58–59, 58, 59, 61–63, **61**, **62**, 67, 442, 467
- folate polyglutamates 53
- folic (pteroylglutamic) acid 53, 54, 58, 59, 62–63, 75, 87, 467
- see also* folate
- folinic acid (formyl THF) 165
- follicles (secondary lymphoid organs) 118, 125, 126, 127, 132, 132, 264, 279
- follicular dendritic cells (FDC) 125, 127
- follicular lymphoma 9, 143, **145**, **147**, 149, **239**, 260, 264, **266**, 266, **267**, 276–278, 277, **278**, 278
- fondaparinux 420, **421**, 422, 432
- fosfatinib 361
- fractures, pathological 290, 291
- free light chains (FLC) 288, **289**, 290, 291, 292
- fresh frozen plasma (FFP) 157, 392, 397, 452, 462, 463, 463, 471
- full blood count (FBC) 350, 359, 365
- fungal infections 161–162, 331, 331
- fusion protein(s) 9–10, 149, 149, 166, 173, 180, 227
- G6PD *see* glucose-6-phosphate dehydrogenase (G6PD)
- G202104 allele/mutation **401**, 403, 408
- gallstones, pigment 67, 68, 69–70
- gamma-carboxylation 387
- gangrene 392
- gastric mucosa B-cell (MALT) lymphoma 142, 280, 281
- GATA1 (transcription factor) 5, 16, 81, 172
- GATA2 (transcription factor) 5, 16
- GATA2 gene mutations 313
- GATA3 284
- Gaucher cells 113, 114
- Gaucher disease 113, 113–115, 114
- G-CSF *see*
- granulocyte colony-stimulating factor (G-CSF)
- gel-based technology, blood groups 458, 458
- GELF criteria, non-Hodgkin lymphoma treatment **269**
- gemtuzumab-ozogamicin (GO) 178
- gene(s) 8–9, 149, 149, 150
- translocations *see* chromosomal translocations
- gene editing 89, 89
- gene mutations 3, 141, **145**, 148, 148–149, 170, 239–240
- see also specific genes*
- gene therapy 89, 96, 377, 378, 379
- genetic counselling, prenatal 89, 97
- genetic disorders of haemoglobin *see* haemoglobin, genetic disorders
- genetic haemochromatosis *see* haemochromatosis
- genetic markers, in neoplasia *see* haematological neoplasia/malignancies
- genetics, glossary 139–141
- Geneva score, revised 412, **412**
- genotyping 365, 459
- germinal centre (GC) **118**, 118, 125, 126, 127, 240, 262, 264
- germline mutations 141, 148, 172, 198, 211, 212, 223, **476**
- GHSG criteria, Hodgkin lymphoma (HL) **253**
- giant cells 294
- Giemsa (G-banding), chromosomes 147
- Gilbert's disease 69, 73
- gilteritinib 182
- Glanzmann thrombasthenia (GT) 365
- glasdegib 166
- globin chains (α , β , δ , γ) 17, 18, 80–81, 80, **82**, 82, **83**, 85, 89, 90, **91**
- see also* thalassaemia
- globin chains (ζ and ϵ) 80
- globin genes 80, 80, 81, 81, 83–86, 84, 85, 89, 89, 90–91, **91**, 96
- globin pseudogenes 80
- glofitamab 273
- glossary, genetics/haematological neoplasia **139–140**
- glossitis, megaloblastic anaemia 57, 57
- Glucksberg score, acute GVHD **330**
- glucocerebrosidase, deficiency 113, 113, 114, 115
- glucose-6-phosphate dehydrogenase (G6PD) 71, 71, 72, 72, 73
- glucose-6-phosphate dehydrogenase (G6PD) deficiency 19, 71–73, 72, **73**, 73, 77
- glucosylceramide 113
- glucosylceramide synthase 113, 115
- L-glutamine, in sickle cell disease 96
- glutathione 71, 71, 73
- glycocalyx/endothelial surface layer (ESL) 349
- glycolytic pathway *see* Embden–Meyerhof pathway
- glycophorins (A, B and C) 20
- glycoprotein (GP), platelet receptors 343
- glycoprotein (GP) 1, β 2 *see* β 2-GP1
- glycoprotein (GP) Ia/IIa 343
- glycoprotein (GP) Ib-IX-V complex 343
- glycoprotein (GP) IIb, abnormalities 365
- glycoprotein (GP) IIb/IIIa *see* GPIIb/IIIa
- glycoprotein (GP) IIIa, abnormalities 365
- glycoprotein (GP) VI 343
- glycosaminoglycans (GAGs) 304, 419
- glycosylphosphatidylinositol (GPI) anchor 316, 316
- glycosyltransferase 453
- gold therapy 314
- 'golf ball' cells 85
- gout 200
- β 2-GP1 407, **407**, 408
- GPIa/IIa (integrin α 2 β 1) 343
- GPIb-IX-V complex 343
- GPIIb, abnormalities 365
- GPIIb/IIIa 8, 342, 343–344, 359, 365, 433, 434
- GPIIb/IIIa receptor antagonists 433
- GPIIIa, abnormalities 365
- G protein-coupled receptors (GPCRs) 343
- GPVI 343
- graft-versus-host disease (GVHD) 316, 324, 325, 327–330, **330**, 331, 332–333, 334, 461, 463
- graft-versus-leukaemia/lymphoma (GVL) effect 324, 325, 327–328, 333–334
- granulocyte(s) 3, 100–103, 101, 101, 157, 215, 462–463
- see also* basophil(s); eosinophil(s); neutrophil(s)
- granulocyte colony-stimulating factor (G-CSF) 4, 5, 5, 6, 102, 103–104, 103, 109, 157, 160, 321, 325, 439
- granulocyte-macrophage colony-stimulating factor (GM-CSF) 6, 103
- 'granulocytic sarcoma' 172
- granulopoiesis 3, 101, 101, 102–103, 103
- Grey (Gray) platelet syndrome (GPS) 364, 364
- growth factor(s) 5, 6–7, **6**, 8, 103
- growth retardation 311
- gum hypertrophy 172, 173
- H63D mutation 44
- H antigen 453, 454
- haem 17, 17, 32, 33, 40, 66
- haemangioblasts 2
- haematocrit **21**, 198, **199**, **469**, **470**, 470–471
- haematological neoplasia/malignancies 3, **127**, 138–167, **139–140**, 141, 144, **145**, 146, **147**, 148–150, 153, 156, 160, 161, **163–165**, 163, 195, 198, 212
- haematoma **357**
- haematuria 96, **357**
- haemochromatosis **43**, 43–45, 44, 45
- haemoglobin 17–18, **17**, 17, 18, 20, 21, **21**, 21, 25, 28, **28**, 33, 37, 66, 68, 72, 73, 80–83, 80, **82**, 90, 132, 157, 441, 452, 466, 468, **469**, 469, 470, **470**
- haemoglobin, genetic disorders 18, 79–98, **82**, 82, 83, 90, 96, 97, 133
- haemoglobin A (Hb A) 17, **17**, 80
- haemoglobin A₂ (Hb A₂) 17, **17**, 41, 80, 89
- haemoglobin Bart's (γ ₄) 83, 84
- haemoglobin C 82, 82
- haemoglobin C disease 94, 96
- haemoglobin Constant Spring 83–84
- haemoglobin D 82, 82, 90
- haemoglobin D disease 96
- haemoglobin D Punjab 82
- haemoglobin E 82, 82, 90
- haemoglobin E disease 96
- haemoglobin F (Hb F) 17, **17**, 18, 41, 80, 81, **84**, 90, 91, 95, 96
- haemoglobin Gower 1 80
- haemoglobin Gower 2 80
- haemoglobin H (Hb H) 83
- haemoglobin H (Hb H) disease 82, 83, **83**, **84**, 85, 88, 90
- haemoglobin-haptoglobin complex 66, 68
- haemoglobin Lepore 90
- haemoglobin Portland 80
- haemoglobin S (Hb S) 18, 82, 90–91, 91, 96
- see also* sickle cell disease
- haemoglobin S/C disease 96
- α -haemoglobin stabilizing protein (AHSP) 85
- haemoglobinuria 66, 68, 69, 76, 77, 443
- haemolysis 66, 66, 68, **68**, 69, **82**, 238, 239, 333, 446–447, 447, 469
- haemolytic anaemia 26, 63, 65–78, **67**, **73**, 91, 406, 442, 443, 444
- haemolytic crises 92
- haemolytic disease of the newborn (HDN) 76, 471–473, **472**
- haemolytic shock phase, transfusion reaction 459–460
- haemolytic uraemic syndrome (HUS) 395, **395**, 397, 398, 443
- haemophagocytic lymphohistiocytosis (HLH, haemophagocytic syndrome) 112, 112, 285, 445
- haemophilia 371–379, **371**, 371–373, **374**, 376–378, 386
- haemophilia A (FVIII deficiency) 371–374, **371**, 371, 372, 373, **386**, 386–387
- haemophilia B (FIX deficiency) **371**, 371–377, 372
- haemophilic pseudotumours 372
- Haemophilus influenzae* type B (Hib) 136
- haemopoiesis 1–10, 2–4, **2**, 7, 8, 9, 101, 103, 133, 140, 195, 204, 211, **214**, 219
- see also* erythropoiesis; granulopoiesis; haemopoietic stem cells (HSC)
- haemopoietic growth factors 3–7, 5, **6**, 7, 8, 316
- haemopoietic progenitor cells 2–4, 3, 6, **6**, 101, 211
- haemopoietic stem cells (HSC) 2–5, 3, 4, 321, 322, 324, 339
- haemopoietic stem cell transplantation (HSCT) 320–336
- see also* stem cell transplantation (SCT)

- haemopoietin receptor superfamily 6
 haemorrhage 20, 23, 180, 200, 203, 356, 372, 424, 425, 464, 469, 472,
see also bleeding; blood loss
 haemorrhagic cystitis 333
 haemorrhagic disease of the newborn (HDN) 388–389
 haemosiderin 28, 33, 36
 haemosiderinuria 66, 316
 haemosiderosis *see* iron overload
 haemostasis 157–158, 338, 338, 343–346, 345, 346, 350, 404, 468
 platelet role *see* platelet(s)
 tests *see* haemostatic function tests
 see also coagulation
 haemostatic function tests 350–353, 352, 353
 haemostatic response 338, 338
 haem-regulated inhibitor (HRI) 17
 ‘hair-on-end’ appearance, skull X-ray 86, 86
 hairy cell leukaemia (HCL) 145, 239, 243–244, 244, 266, 267
 hairy cell leukaemia variant (now SBLPN) 243
 ‘hand–foot’ syndrome 91, 93
 H antigen 453, 454
 haploid, definition 145
 haplo-identical stem cell transplants 321, 323
 haptocorrin (R-factor) 51, 53
 haptoglobins 66, 67
 Hashimoto disease 443
 Hayflick limit 3
 Hb *see* haemoglobin; *specific types of haemoglobin*
 Hb F *see* haemoglobin F (Hb F)
 Hb S *see* haemoglobin S (Hb S)
 heart, in systemic (primary) AL amyloidosis 305
 heart failure 142, 333
 heart valves, mechanical 428
 Heinz bodies 25, 72, 73, 83, 132
Helicobacter pylori 53–54, 142, 263, 280, 361
 helix–loop–helix motif 5
 HELLP syndrome 395, 468
 hemojuvelin (HJV) 30, 31, 45
 HEMPAS 318
 Henoch–Schönlein syndrome 368, 368
 heparin 362, 418, 419–422, 419, 420
 heparin-induced thrombocytopenia (HIT) 393–394, 394, 430
 heparinoids 419, 419, 420
 heparin sulfate 419
 hepatitis, viral 314, 442, 456, 456
 hepatitis B 87, 89, 456
 hepatitis C 87, 89, 375, 456
 hepatitis E, transfusion-transmitted 456
 hepatocellular carcinoma 44, 87
 hepatomegaly 86, 266
 hepatosplenomegaly 472
 hepcidin 30, 31, 35, 37, 39, 44, 45
 hephaestin (ferrioxidase) 33
 hereditary coagulation disorders *see* coagulation disorders
 hereditary elliptocytosis (HE) 69, 70, 71
 hereditary haemolytic anaemias 67, 67, 69–74, 69, 70
 hereditary haemorrhagic telangiectasia (HHT) 367, 367–368
 hereditary persistence of fetal haemoglobin (HPFH) 84, 90, 96
 hereditary pyropoikilocytosis 71
 hereditary spherocytosis (HS) 69–71, 68, 69, 70, 71
 hereditary stomatocytosis 70, 71
 hereditary systemic amyloidosis 303, 308
 herpes simplex virus (HSV) 161, 173, 331–332
 herpes viruses 161, 456, 456
 herpes zoster virus 238
 heterophile antibodies 126, 128
 heterozygosity 150
 hexose monophosphate shunt 19
 HFE gene mutation 44, 45
 HFE protein 30, 31, 44
 Hickman catheter 156
 high-dose immunoglobulin 76
 high molecular weight kininogen (HMWK) 345
 high-performance liquid chromatography (HPLC) 87, 88
 high-resolution computed tomography (HRCT) 161
 histiocyte(s) 111, 112, 112
 see also macrophage(s)
 histiocytic cell disorders 111, 112–113, 285, 476
 histiocytic sarcoma 113
 histiocytosis, ALK-positive 113
 histone(s) 9, 150, 212
 histone deacetylase 3 31
 histone deacetylase inhibitors 164
 HIV infection 87, 126, 142, 248, 263, 272, 275, 276, 375, 445–446, 446, 456
 HLA-A 325, 327, 329
 HLA-B 325, 327, 329
 HLA-C 325, 327
 HLA-DR 325, 327, 329
 HLA-DRB gene 328, 329
 HLA-matching donor, allogeneic stem cell transplantation 321, 323, 325
 HLA region (chromosome 6) 325, 326, 327
 HLA-restricted T cells 125, 325–327
 HLA system 119, 121, 125, 321, 323, 325–328, 327, 328, 329, 341, 461
 HLA typing 327–328
 Hodgkin cells 247, 248, 249
 Hodgkin lymphoma (HL) 141, 152, 246–258, 247, 249, 250, 251, 252, 253, 254–256, 260, 264, 334, 439, 446
 Homan’s sign 408
 homocysteine 58–59, 61, 404, 415
 homocystinuria 404
 hookworm 35, 37
 hormone replacement therapy (HRT) 404
 hospital-acquired thrombosis (HAT) 405
 Howell–Jolly bodies 25, 87, 94, 132, 132
 HPA-1a 471
 HS-40 region 81
 H substance 453
 5-HT₃ receptor antagonists 158
 human albumin solution 463
 human herpes virus 6 infection (HHV-6) 332
 human herpes virus 8 infection (KSHV/HHV8) 142, 285
 human immunodeficiency virus *see* HIV infection
 human leucocyte antigen (HLA) *see* HLA system
 human platelet antigens (HPA) 340
 human T-cell lymphotropic virus type 1 (HTLV-1) 141, 244, 245, 285, 456, 456
 human T-cell lymphotropic virus type 2 (HTLV-2) 456, 456
 hydrogen peroxide 105
 hydrops fetalis 82, 83, 83, 84, 472, 473
 hydroxycarbamide (hydroxyurea) 95, 163, 165, 190–191, 200, 201, 204, 206
 hyperbilirubinaemia 473
 hypercalcaemia, multiple myeloma 289, 290, 291, 291, 298
 hypercoagulability 392, 400, 468
 hyperdiploidy 145, 152, 227, 233
 hypereosinophilic syndrome (HES) 110, 208
 hyperferritinaemia, causes 43
 hyperfibrinolysis 352, 390, 391, 391
 see also fibrinolysis
 hypergammaglobulinaemia 113
 hyperhaemolysis syndromes 461
 hyperhomocysteinaemia 404, 415
 hyperleucocytosis 300
 hyperproteinaemia, VTE risk 406
 hypersplenism 135, 447
 hyperviscosity 199, 200, 300, 300, 406
 hyperviscosity syndrome 280, 291, 291, 300, 300, 406
 hypocalcaemia 158
 hypochromic anaemias 27–41, 23, 28, 35, 37, 39, 89
 hypodiploidy 145, 227
 hypomethylating agents (HMAs) 178, 179, 182, 219
 hyposplenism 135, 135, 136, 136
 hypotension, persistent, pulmonary embolism 413
 hypothyroidism 443
 hypoxia 14–15, 15, 30, 198, 202
 hypoxia-inducible factors (HIF α , HIF β) 14, 15
 ibrutinib 241
 idarucizumab 428
 idelalisib 242
 IDH1, drugs targeting 182
 IDH1 and IDH2 genes 9, 150, 171
 idiopathic cytopenia of undetermined significance (ICUS) 109, 214, 219
 idiopathic dysplasia of undetermined significance (IDUS) 214, 219
 idiopathic thrombocytopenic purpura (ITP) *see* immune (idiopathic) thrombocytopenic purpura (ITP)
 IgA, IgG, IgM *see* entries beginning immunoglobulin
 IgM MGUS *see* monoclonal gammopathy of undetermined significance (MGUS)
 JGVH gene, chronic lymphocytic leukaemia 240, 241
 IKZF1 gene deletion 223
 imatinib 166, 189, 191
 imiglucerase (Cerezyme) 113
 immune cell-associated neurotoxicity syndrome (ICANS) 167
 immune checkpoint inhibitors 165, 166
 immune complex-mediated thrombocytopenia 442
 immune drug-induced thrombocytopenia 356, 362, 362, 363
 immune response 100, 121, 125, 125, 127
 immune thrombocytopenic purpura (ITP) 74, 359–362, 360, 361, 468
 immunoblasts 283
 immunodeficiency 106, 129, 129, 263
 immunoglobulin(s) 118, 119, 121–123, 121, 122, 123, 127, 143, 151, 150, 223, 239–241, 243, 247, 288, 291, 291, 294, 304, 361, 387, 393, 464
 immunoglobulin A (IgA) 121, 121
 immunoglobulin A (IgA) paraprotein 290, 292, 298, 300
 immunoglobulin D (IgD) 121
 immunoglobulin E (IgE) 121
 immunoglobulin G (IgG) 74, 75, 121, 121, 453, 456, 471, 473
 immunoglobulin G (IgG) paraprotein 147, 290, 292, 298, 300
 immunoglobulin M (IgM) 76, 121, 121, 128, 288, 452, 453, 457, 459, 473
 immunoglobulin M (IgM) paraprotein 76, 147, 280–282, 288, 290, 298, 300

- immunoglobulin superfamily 7, 343
immunohistology/immunohistochemistry 152, 152, 264, **265**, 267
immunological memory 117
immunomodulatory drugs 166
immunoparesis 291
immunoperoxidase stain 267
immunophenotyping *see specific disorders*
immunosuppression 159–162, 238, 262
immunosuppressive drugs/treatment 75, 315, 323–325, 361, 386–387
immunothrombosis 392–393
indirect antiglobulin test (IAT) 458, 459
ineffective erythropoiesis 24–26, 26, 29, 30, 318
infants 2, 2, 228, 468, 470
infection(s) 87, 94, 103, **109**, 109–110, 112, 126, **127**, 128, 129, 134, **135**, 136, 141–143, 159–162, 172, 173, 231, 290, 291, 299, 330–333, **330**, 331, 332, **358**, 359, 363, 443–448, **444**, **453**, 455–457, **456**, 462
infection-associated haemolytic uraemic syndrome (IA-HUS) 397
infectious mononucleosis 126, 128, 128, 134, **135**
inferior vena cava (IVC) filter 430
inferior vena cava (IVC) thrombosis 409
infertility 158
inflammation **38**, 38–39, 105, 304, 392–393, 438, **438**, 448
inflammatory response, to tissue injury 448–449
inherited coagulation disorders 382–384
inherited platelet disorders (IPDs) 364, 364–365, 365, 366–367
innate immune system 100, 121
inotuzumab ozogamicin 233
integrin(s) 7–8, 343–344
integrin $\alpha 2\beta 1$ (GPIIb/IIIa) 343
integrin $\alpha \text{IIb}\beta 3$ *see* GPIIb/IIIa
interferon- α (α -interferon) **164**, 166, 192, 201, 204, 244
interferon- γ (IFN- γ) 6, 39, 125
interleukin-1 (IL-1) 6, 103
interleukin-1 β (IL-1 β) 39
interleukin-2 (IL-2) 125
interleukin-3 (IL-3) 6, 103
interleukin-4 (IL-4) 117, 125
interleukin-5 (IL-5) 6, 103
interleukin-6 (IL-6) 30, 39, 103, 340, 391–392, 406
interleukin-7 (IL-7) 6, 117
interleukin-10 (IL-10) 125
interleukin-11 (IL-11) 103
intermittent compression devices 432
International Consensus Classification (ICC) 477
international normalized ratio (INR) 351, 424, **424**, **425**, 426
International Prognostic Index (IPI) 271, **273**
International Prognostic Scoring System (IPSS), Hodgkin lymphoma **253**
International Staging System (ISS), multiple myeloma 294, **295**
International T-cell Lymphoma Project 283
interphase 8
interstitial pneumonitis 332, 332
intestinal T-cell lymphomas 285
intracardiac thrombosis 400
intracerebral bleeding 359
intracranial haemorrhage, neonatal 468
intravascular haemolysis 66, 66, 68, **68**, 69
intravenous immunoglobulins (IVIg) 361, 387, 393, 464
intrinsic factor (IF) 51, 52, 53–55
intrinsic pathway, coagulation 347, 350–351, 351
intrinsic Xase, and emicizumab 377
iron 17, 18, **21**, 23–24, 28–31, **28**, 29, 30, 31, 32–35, **32**, 33, 36, 37–38, **43**, 43–45, 317, 466, 467
iron chelation therapy 47–49, **48**, 86, 87, 90, 316
iron deficiency 17, 28–30, 32, 31, 33–38, 33, **34**, 35, 36, 41, 316, 440, 442, 447, 466
iron deficiency anaemia 21, 28, 28, 33–35, 33, 35, 36, **37–39**, 37–39, 41, 466–467
iron dextran 38
iron infusion, in pregnancy 466
iron overload 29, 30, 31, 35, 36, 42–49, **43**, 45, 46, 47, 86–87, 95, 317, 333, 462
iron refractory iron deficiency anaemia (IRIDA) 39, **39**
iron regulatory protein (IRP) 29, 30, 32
iron response elements (IRE) 29, 30, 32
iron sucrose 442
ischemic stroke, acute 435
isochromosome 147–148
isocitrate dehydrogenase (IDH) 1/2, inhibitors 166
ISTH (International Society of Thrombosis and Haemostasis) **371**, 391
ISTH-BAT (bleeding assessment tool) 357
ITP *see* immune thrombocytopenic purpura (ITP)
ivosidenib **164**, 166, 179
ixazomib 166, 298

JAK2 6, 144, 149, 195, 196
JAK2 gene mutation 6, 141, 144, 149, 195–196, 195–197, 198–204, **202**, 206, 224, 406
JAK2 inhibitors 112, 136, 166, 202, 204, 206, 329
JAK/STAT pathway 6, 8, 112
Janus-associated kinase (JAK) proteins 6
jaundice 56–57, 57, 69, 72, 73, 472
juvenile myelomonocytic leukaemia (JMML) 208
juvenile xanthogranuloma 113

kala-azar 447, 447
karyogram 145, 147
karyotypes, analysis 150
kernicterus 472
Khorana score 406
Ki67 279
kidney 94, **289**, 290, 294, 305, 308
see also entries beginning renal
KIT (CD117) 4, 144
KIT mutation, Asp816Val (D816V) 207
Kleihauer test 472, 472
KMT2A (MLL) gene 150, 224, 228
koilonychia (spoon nails) 22, 34
Kostmann syndrome 109
KRAS gene mutations 294
KRd therapy 296
KTM2A (MLL) gene 141

lactate dehydrogenase (LDH) 24, 60, 68, 294, 295, 397
lactoferrin 105
lamin B receptor 106
Langerhans' cell(s) 111–112
Langerhans cell histiocytosis (LCH) 112–113
large B-cell lymphoma **261**, 266, 268, 271–275, 272–275, 284
large granular lymphocyte (LGL) leukaemia **145**, 244
LBR gene mutation 106
lead poisoning 40–41
lectin pathway 124, 124
left ventricular failure 92

Leishman–Donovan bodies 447
lenalidomide 166, 218, 296, 297
Lepore syndrome 86
letermovir 332
leucine zipper 5
leucocyte(s) *see* white blood cell(s) (WBC)
leucocyte adhesion molecules 105, 106
leucocyte chemotactic factor II (ALEC2) amyloidosis **303**, 308
leucocytosis 110, **110**, 111, 180, 186, 188
see also lymphocytosis
leucodepletion 462
leuco-erythroblastic reaction 108, **108**
leukaemia 141, 146, **163–165**, 169, 186
see also specific leukaemias
leukaemoid reaction 108, 186, 439, 443
light chains *see* free light chains (FLC); *under* immunoglobulin(s)
light transmission aggregometry (LTA) 352, 353, 365
lineage-committed progenitor cells 3, 3, **6**
lineage-defining markers (Lin) 2
'linked sausage' effect, retinal vessels 300
lipid bilayer membrane 19, 20
liposaccharide 39
livedo reticularis 407
liver 2, 5–6, 47, 47, 49, 92
liver biopsy 44, 44, 45, 46
liver disease 87, 333, **388**, 389, 428, **442**, 442–443, 443
liver tumours **442**
locus control region (LCR), globin gene cluster 81
Loeffler syndrome 111
'log kill' hypothesis 162
loiasis 448, 449
long-term haemopoietic stem cells 2
loss of heterozygosity (LOH) 150
lower limbs, DVT 408, 409, 409, 414, 414
low-molecular-weight heparin (LMWH) 157, 418, 419–420, 419, **420**, **421**, 422, 426, 428–430, 468
LP cells ('popcorn' cells) 249, 249
lumbar puncture, in ALL 226
lupus anticoagulant (LA) **352**, 407, 408, 441
luspatercept 40, 88, 90, 217
lymphadenopathy 126, 129, 130, 225, 225, 238, 238, 247, 247, 260, 265, 271, 276
lymph node(s) 117, **118**, 118, 125, 126, 127, 129, 264, 264, 267, 279
lymphoblast(s) 223, 226, 226
lymphoblastic lymphoma 225, 260, 276
lymphocyte(s) 3, 12, **12**, 100, 100, 117, 117–121, 260, 445
see also B lymphocytes; T lymphocytes
lymphocyte count **12**, **21**, **100**, 445
lymphocytosis 125–128, 237, 238, 244
lymphoid growth factors **6**
lymphoid neoplasms, classification **476**, 477, **477**
lymphoid organs 117, 118
lymphoma 74, 142, 159, **163–165**, 238, 241, 243, 247, 260, 260
lymphopenia 128
lymphoplasmacytic lymphoma (LPL) **145**, 264, **266**, 267, 280–282, 281, 282, 290, 300
lysosomal storage diseases 113–115
lysosomes 105
lysozyme 105

macrocyte(s) 24, 59, 59–60, 60, 63
macrocytic anaemia **23**, 51–64, 59, 60, **63**
macrocytosis 58, 443

- α 2-macroglobulin 348
 macrophage(s) 29, 30, 31, 35, 36, 39, 66, 66, 74, 101, 104, 105, 124, 132, 133, 216, 276, 447
 macrophage colony-stimulating factor (M-CSF) 6, 7
 macrothrombocytopenia, inherited 364
 magnetic resonance imaging (MRI) 44, 46–47, 47, 47, 92, 93, 134, 272, 291, 292, 372, 412
 magnetic resonance pulmonary angiography 413
 major histocompatibility complex (MHC) 325
 malabsorption 56, 56
 malaria 25, 72, 77, 91, 102, 134–136, 143, 446–447, 447, 457
 malignant disease 9, 38, 38, 59, 140–141, 142, 143, 256, 333, 438–440, 438, 439, 440, 440
 see also haematological neoplasia/malignancies
 MALT lymphoma 142, 266, 267, 280, 281
 mannose-binding lectin (MBL) pathway 124, 124
 Mantle Cell International Prognostic Index (MIPI) 279
 mantle cell lymphoma (MCL) 8, 145, 152, 239, 264, 266, 266, 267, 278–279, 280
 MAP2K1 gene mutation 244
 MAPK pathway 6–7, 112
 march haemoglobinuria 77
 marginal zone lymphomas 262, 264, 268, 279–280
 massive transfusion syndrome 363, 392
 mast cell(s) 206
 mast cell leukaemia 207
 mast cell sarcoma 207
 mastocytosis 145, 195, 196, 206–207, 208
 matriptase 2 30, 39
 May–Hegglin anomaly 106, 107
 MCH *see* mean corpuscular haemoglobin (MCH)
 MCL1 237
 MCV *see* mean corpuscular volume (MCV)
 MDS *see* myelodysplastic syndromes (MDS)
 mean corpuscular haemoglobin (MCH) 21, 28, 33, 83, 466
 mean corpuscular volume (MCV) 21, 22, 28, 33, 51, 59, 60, 63, 83, 89, 466, 468, 469, 469
 measurable residual disease (MRD) 152–153, 153
 mediastinal mass 225, 247, 248, 268
 Mediport 156–157
 megakaryoblast 339
 megakaryocyte(s) 3, 3, 195, 202, 204, 215, 216, 339, 339, 340, 340, 343, 359, 364, 446
 megakaryopoiesis 3, 339, 339, 360, 364
 megaloblastic anaemia 26, 51–63, 51, 54, 55, 57, 59, 60, 62, 107
 melanin skin pigmentation 44, 45, 58
 melphalan 162, 163
 membrane inhibitor of reactive lysis (MIRL) 316
 menadione 388
 meningeal syndrome 225
 menopause 158
 menorrhagia 34, 36, 356, 357, 359, 379, 382
 mepolizumab 111
 mercaptopurine 164
 mesenchymal stem cells 4
 Mesna 333
 metamyelocytes 60, 60, 101, 101, 102, 108, 443
 metastatic disease, bone marrow aspirates 438, 439
 methaemalbumin 66, 68
 methaemalbuminaemia 68
 methaemoglobinaemia 18, 82, 83
 methotrexate 54, 163, 165, 231, 233
 methylation, DNA 9, 148, 150
 methylcobalamin, structure 51, 51
 methyl dopa 77
 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) 58, 404
 ‘methylfolate trap’ 53
 methylmalonic acid, measurement 61
 methylmalonyl coenzyme A (CoA) 53, 53
 methyltetrahydrofolate (methylTHF) 53, 54
 MGUS *see* monoclonal gammopathy of undetermined significance (MGUS)
 Micera 16
 microangiopathic haemolytic anaemia (MAHA) 77, 77, 77, 333, 395, 397, 438
 microangiopathies, thrombotic (TMA) *see* thrombotic microangiopathies (TMA)
 microbicidal mechanisms 105, 106–108
 microbicidal proteins 105
 microcyte 24, 28
 microfilarial infections 448
 β 2-microglobulin 294, 326
 microplate blood group serology 457, 458
 microRNAs 150, 239
 microspherocyte 24
 microthrombi 391, 395–396, 396, 397
 microvascular thrombosis, in TTP 396
 midostaurin 207
 miglustat 115
 minimal residual disease (MRD) 152–153, 153
 see also specific neoplasms
 minor histocompatibility antigens 327–328
 MIPSS-70+, prognostic model 206, 207
 mitapivat 73
 mitochondria, platelets 342
 mitogen-activated protein (MAP) kinase 6
 mitosis 8
 mitotic recombination 150
 mixed erythroid and megakaryocyte progenitor 3, 3
 mixed lymphocyte, granulocyte and monocyte progenitor 3, 3
 molecular genetics *see specific neoplasms/diseases*
 monoblast(s) 104
 monoblastic leukaemia 174
 monoclonal antibodies (therapeutic) 75, 165, 166, 178, 178
 see also specific drugs (e.g. rituximab)
 monoclonal B-cell lymphocytosis (MBL) 147, 237
 monoclonal gammopathy of undetermined significance (MGUS) 113, 144, 147, 288, 289, 290, 298–300, 299, 304
 monoclonal immunoglobulins 76, 288, 288
 see also paraprotein(s)
 monocyte(s) 3, 12, 21, 100, 100, 100, 101, 102–108, 110, 110
 monocyte colony-stimulating factor (M-CSF) 103
 monocytoïd cells 216
 monocytosis 110, 110
 Monofer 38
 monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) 285
Moraxella catarrhalis 263
 MPL gene, TPO-R encoded 340
 MPL gene mutation 195, 195, 196, 197, 202, 204, 206
 M-protein *see* monoclonal immunoglobulins
 MRD (minimal residual disease) 152–153, 153
 mRNA 29, 81, 212
 MT2A 5
 mTORC1 17
 mucin-secreting carcinomas 77
 mucosal haemorrhages/bleeding 312, 356, 357, 359
 mucositis 159, 160, 333
 multidetector CT pulmonary angiography (CTPA) 411, 413
 multiple myeloma 141, 144, 147, 159, 264, 288–299, 288, 289, 289, 290–295, 295, 296, 303, 304, 304, 307, 406
 multipotent lymphoid/myeloid progenitor cells 3, 3, 6
 MUM1, in B-cell lymphomas 266, 271
 mutations *see* gene mutations
 MYC gene (oncogene) 149, 150, 271, 273, 275, 294
 mycophenolate mofetil (MMF) 325
Mycoplasma pneumoniae 443
 mycosis fungoides 282, 283
 MYD88 (*L265P*) gene mutation 76, 281
 myeloblasts 101, 101, 170
 myelocytes 101, 101, 108, 216
 myelodysplastic neoplasms *see* myelodysplastic syndromes (MDS)
 myelodysplastic syndromes (MDS) 40, 48, 63, 104, 145, 147, 170, 170, 210–221, 211, 212, 212, 213, 213, 214, 215–218, 312, 315, 366, 438, myelodysplastic syndromes/myeloproliferative (MDS/MPN) neoplasms 219–220, 220
 myelofibrosis 200, 204, 205
 myeloid growth factors 6
 myeloid leukaemia *see* acute myeloid leukaemia (AML); chronic myeloid leukaemia (CML)
 myeloid leukaemia of Down syndrome (ML-DS) 172
 myeloid/lymphoid neoplasia with eosinophilia 208
 myeloid neoplasms 172, 195, 476
 see also myeloproliferative neoplasms (MPN)
 myeloid sarcoma 172
 myeloma *see* multiple myeloma
 myeloperoxidase deficiency 106
 myelopoiesis 2
 myeloproliferation, genetic drivers 195–198
 myeloproliferative neoplasms (MPN) 53, 111, 145, 172, 194–209, 195, 195–197, 196, 212, 366, 406
 myelosuppression, CAR-T cell infusion causing 167
 MYH9 gene mutations 106
 myoglobin 28, 28
 MYSEC-PM, prognostic model 206, 207
 nailbed, pallor, in anaemia 22, 22
 natural killer (NK) cells 3, 3, 12, 12, 100, 121, 326
 nausea and vomiting 158
 navitoclax 206
NBEAL2 gene 364
 NCCN-IPI 273
 necrosis 10
Neisseria meningitidis 136
 neonatal haematology 20, 21, 22, 33, 34, 72, 73, 356, 468–471, 469, 469, 470
 neonatal purpura fulminans 403
 nephrocalcinosis 294
 nephrotic syndrome 406, 442
 NETosis 105, 106, 393
 NETs (neutrophil extracellular traps) 105, 106, 390, 393
 neural tube 58, 62
 neural tube defect (NTD) 58, 58, 59, 62, 467
 neurofibromatosis 208
 neuropathy, vitamin B₁₂ deficiency and 57–58, 58, 61
 neurotoxicity, CAR-T cell infusion causing 167
 neutropenia 104, 108–110, 109, 157, 159, 160–162, 160, 173, 213, 244, 266, 439, 446, 471
 neutrophil(s) 3, 12, 59, 60, 100–103, 100–102, 104–106, 105–107, 108, 109, 107, 124, 132, 135, 202, 213, 445, 445

- neutrophil count **12, 21, 100**, 102, 207, 314
 neutrophil disorders 104–108, **104**, 107, 213
 neutrophil extracellular traps (NETs) 105, 106, 390, 393
 neutrophilia *see* neutrophil leucocytosis
 neutrophil leucocytosis (neutrophilia) 107, 108, **108**, 108, 186, 220, **220**, 443, 445
 neutrophil-specific granule deficiency 106
 newborn infants *see* neonatal haematology
 next generation sequencing (NGS) 150–151, 153, 153, 229, 365
 NFκB pathway 262, 279, 290
 nicotinamide adenine dinucleotide phosphate (NADP) 71
 nicotinamide adenine dinucleotide phosphate, reduced (NADPH) 18, 19, 71, 105
 Niemann–Pick disease 115
 night sweats 247, 265
 nilotinib 166, 189, **191**
 nitric oxide (NO) 105
 nitric oxide synthase 105
 nitrous oxide (N₂O) 53, 63
 NK/T-cell lymphoma, extranodal 284, 285, 285
 nodal marginal zone lymphoma 280
 nodular lymphocyte-predominant B-cell lymphoma **250**
 nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) 247, 249, **250**, 257, 260
 nodular sclerosis 249
 nodular T-follicular helper cell lymphoma 283–284
 non-Hodgkin lymphoma (NHL) 141, **145**, **147**, 237, 244, 259–269, 260, **261**, **263**, **265**–**267**, 266–268, **269**, 270–286, 334, 439, 446
see also specific lymphomas
 Noonan syndrome 208
 normal values **21, 100**, 448, **469**
see also specific cell types/parameters
 normoblasts *see* erythroblasts (normoblasts)
 NOTCH1 5, 6, 224, 229
 NOTCH1 mutation, in CLL 239–240
 NOTCH signalling pathway 224, 228, 229
 NPM1 gene mutation 143, 149, 152, 170, 175
 Npr3 gene 17
 NRAS gene mutations, in myeloma 294
 NT-proBNP 305
 nucleophosmin 149
 nutritional support, in malignant disease 159
- obesity, direct-acting oral anticoagulants 428
 obinutuzumab 241, 242
 obstructive shock 413
 oestrogen therapy, venous thrombosis risk 404–405
 omacetaxine **164**, 192
 oncogenes 143–144, **144**, 149, 149, 150, 170, 262, 271, 273, 275, 294
 open canicular system (OCS), platelets 342
 opsonization 105, 106, 124, **124**
 oral contraceptives, VTE risk 404
 oral mucositis 159, **160**, 333
 Oroya fever 443
 osmotic fragility test 70
 osteolytic lesions, multiple myeloma 290, 291
 osteopenia, in β-thalassaemia major 87–88
 osteopetrosis 318
 osteoporosis 113, 291
 osteosclerotic myeloma (POEMS syndrome) 298
 ova, fertilized, storage 158–159, 251
 oxidant stress, acute haemolytic anaemia, in G6PD deficiency 72
 oxygen (O₂) 14, 15, **15**, 16, 18, **18**, 21, 441
- oxygen-dependent microbial destruction 105
 oxygen-independent microbial destruction 105
 oxyhaemoglobin 17
- P2Y12 receptor antagonists 432, 433, 434
 p53 8, 9
gene see TP53 gene
 p190 protein 186, 187
 p230 protein 186
 packed cell volume **21**
see also haematocrit
 pain 159, 290, 412
 palifermin 159
 pallor, anaemia 22, 22
 pancytopenia 22, 108–109, 211, 213, 243, 310, 311, **310**, **440**
see also cytopenia
 Pappenheimer bodies 25, 132, 135
 PAR1 inhibitor 433, 434
 paraplegia, compression 299
 paraprotein(s) **147**, **282**, 288, **288**, **289**, 290, 291, 298–300, 304
 paraproteinaemia 122, 288, **366**
 parasitic infections *see* protozoan/parasitic infestations
 parietal cell antibodies 54
 paroxysmal cold haemoglobinuria 76, 443
 paroxysmal nocturnal haemoglobinuria (PNH) 67, 314, 316, **316**, 316–317, 406, 408
 parvovirus B19 67, 318, 319
 passenger mutations 144
 pathogen-associated molecular patterns (PAMPs) 393
 PAX5 5
 PD-1 inhibitor 254, 255, 256
 PD1 ligand (PDL1) 249
 PDE inhibitors 433, 434
 PDGFRA 144
 PDGFRA gene fusion 208
 PDGFRB gene fusion 208
 PD-L1 256
 Pearson syndrome 40, 313
 pegcetacoplan 76, 317
 pegfilgrastim 103
 PEGylation, coagulation factor half-life extension 374
 Pelger–Huët anomaly 106, **107**
 pemigatinib 208
 pencil cell (red cells) 24, 35, 35
 penicillin 76, 77, 136, 161
 pentose phosphate shunt 19, 73
 pentostatin (deoxycoformycin; DCF) **164**, 244
 periarterial lymphatic sheath (PALS) 132
 peripheral blood stem cells (PBSC) 104, 321, 325
see also stem cell transplantation (SCT)
 peripherally inserted central catheters (PICC) 157
 peripheral T-cell lymphoma (PTCL) 283–285, **284**
 Perl's (Prussian blue) reaction 28, **43**, 44, 69, 215, 216
 pernicious anaemia (PA) 54–55, **56**, 62
 peroxisomes, platelets 342
 petechiae 356, **357**, 359, 367
 PET scan and PET/CT *see* positron emission tomography (PET)
 PFA-100 test 352
 PFA-200 test 352
 phagocyte(s) **12**, **12**, 100, 105–108, **106**
see also basophil(s); eosinophil(s); granulocyte(s); monocyte(s); neutrophil(s)
 phagocytosis 105, **105**, 106, **360**
 Philadelphia (Ph) chromosome 186, **187**, 227
see also BCR::ABL1 gene rearrangement
- phosphatidylinositol glycan 316
 phosphatidylinositol (3,4,5)-trisphosphate (PIP3) 118, **119**
 phosphatidylserine (PS) 344, 390
 phosphodiesterase (PDE) 433, 434
 phosphatidylinositol 3-kinase (PI3K) 6–7, 8, 118, **119**, 242, 343
 phospholipase C (PLC) 343
 phospholipid (PL) 407
 PIGA gene mutation 314, 316
 pigment (bilirubin) gallstones 67, 68, 69–70, 92
 pirtubrutinib 166
 PIVKAs 422
 PKLR gene mutations 73
 placenta, foetal haemopoiesis 2
 plasma 20, 448, **449**
 plasma cell(s) **117**, 118, 121, 125, **127**, 262, 288, 289, 291, 446
 plasma cell leukaemia 298
 plasma cell neoplasms 287–301, **290**
MGUS see monoclonal gammopathy of undetermined significance (MGUS)
multiple myeloma see multiple myeloma
 plasmacytoma *see* plasmacytoma
 plasmacytoma **290**, 298
 plasma preparations 452, 463–464
 plasmin 348–349, **349**, 435
 plasminogen **345**, **376**
 plasminogen activator inhibitor-1 (PAI-1) **345**, 348, 349, **349**, 390, 404, 435
 plasminogen activator inhibitor-2 (PAI-2) 348, 349, **349**
Plasmodium falciparum malaria see malaria
 platelet(s) 2, 3, **12**, **12**, 135, 203, 214, 338, 338–344, **338**–**342**, **344**, 352, 353, 358, **358**, 359, 360, 362–366, **363**–**365**, **366**, 387, 390, 390, 393, 400, 432, 433, 439, **440**, **441**, 442, 443, 471,
 platelet concentrators 463
 platelet count **12**, **21**, **22**, 35, 136, 314, 176, 202, 203, **204**, 339, 358, 362, 406, 467, **469**
 platelet disorders 202, **203**, **204**, 350, 358, **358**, 363–367, 364, 365, **366**, 387, 439, **440**, **441**, 442, 443
see also thrombocytopenia
 platelet factor 4 (PF4) 390, 393, **394**
 platelet transfusions 157, 218, 361, 367, 392, 462, 463
 platinum derivatives 166
 plerixafor 96, 321
 ploidy 145, 226, 227
see also hyperdiploidy
 pluripotent stem cells 2, 3, **3**, **6**
mutation, cell proliferation see myeloproliferative neoplasms (MPN)
 PML::RARα fusion protein 173
Pneumocystis jirovecii (carinii) 162, 231, 331, 332, 332
 POEMS syndrome 298
 poikilocyte 24, 35, 35, 205, 206
 poikilocytosis 24, 73
 Polarix trial 271
 polatuzumab vedotin 271
 polycystic kidney disease (PKD) 441
 polycythaemia 15, 20, **82**, 83, 198, **198**, 202, 202, 438, **441**, 470–471
 polycythaemia vera (PV) 195, **195**, **196**, **197**, 198–202, **199**, **199**, 200, 205, 448
 polymerase chain reaction (PCR) 97, 152, **153**, 373
 polymorphs *see* neutrophil(s)
 polymyalgia rheumatica 441

- pomalidomide 166, 296, 297
 ponatinib 189, **191**
 'popcorn' cells 249, 249
 Port-a-cath 156–157
 portal hypertension 135, **135**
 posaconazole 177
 positron emission tomography/computed tomography (PET/CT) 134, 248, 250, 252, 254–255, 264, 268, 272
 positron emission tomography (PET) scans 134, 134, 250, 252, 264, 268, 291, 292, 334, 335
 post-capillary venules 121
 postoperative venous thrombosis 405, 408
 post-thrombotic syndrome (PTS) 414, 414
 post-transfusion acute circulatory overload (TACO) 461
 post-transfusion purpura 362, 462
 post-transplant lymphoproliferative disease (PTLD) 334, 335
PPMID gene mutation 144
 prasugrel 432–433, 434
 prednisolone 75, 361
 pregnancy 32, 34, 62, 76, 95, 362, **395**, 404–405, 407, **407**, 428, 453, 455, 466, 466–468, 467, 471–472, **472**
 prekallikrein (Fletcher factor) **345**
 prenatal counselling 89, 97
 preterm infants 468, 470
 priapism 92, 95
 'prickle' cells 73
 primary central nervous system lymphoma 275
 primary cold agglutinin disease 76
 primary extranodal lymphoma 260
 primary mediastinal B-cell lymphoma (PMBCL) 268, 271, 275, 275
 primary myelofibrosis (PMF) 136, 195, **196**, 197, 204–206, **204**, 205, **207**
 prions, transmission by transfusions **456**, 457
 procoagulants 344, **345**
 progenitor cells 2–3, **3**, **6**, 101, 117
 see also haemopoietic progenitor cells
 progesterones 158
 programmed cell death *see* apoptosis
 prolyl hydroxylase (PHD2) 15, 15, 16
 prolymphocyte 243, 243
 promonocytes 104
 promyelocytes 101, 101, 108
 pronormoblast 12, 13, 14, 14
 proplatelets 339, 339, 340, 364
 prostacyclin, synthesis 344
 protamine 422
 protease-activated receptor 1 (PAR-1), inhibitor 433, 434
 protein 4.1 20
 protein 4.2 20
 protein Bb 124
 protein C (PC) **345**, 348, 348–349, 403, 471
 protein kinase C (PKC) 343
 protein S (PS) **345**, 348–349, 393, 403–404
 prothrombin (FII) 218, 315, **345**, 347, 383, 403
 prothrombinase 345
 prothrombinase complex 347
 prothrombin time (PT) 351–352, 351, **352**, 392, 408, 424, 428, 471
 prothrombotic state 87, 400
 proto-oncogenes 143, 144
 protoporphyria 17, 66
 protozoan/parasitic infestations 143, 446–448, 447, 448, 449, **456**
 pruritus 199, 202, 282
 P-selectin 393
 P-selectin glycoprotein ligand-1 (PSGL-1) 393
 pseudodiploid cell 145
 pseudo-Pelger abnormality 213, 216
 pseudo-Pelger-Huët abnormality 445
 pseudopolycythemia 20, 198, 202
 pseudoxanthoma elasticum 368
 psychological support, in malignant disease 158
 pteroylglutamic acid *see* folic (pteroylglutamic) acid
 puerperium, venous thrombosis risk 404–405
 pulmonary angiography 413
 pulmonary arteries, thrombosis 412
 pulmonary artery pressure 412
 pulmonary complications, stem cell transplant 333
 pulmonary embolism (PE) 395, 400, 401, 408–414, **410**, **412**, **413**, 418, 423, 430–432, 435
 pulmonary embolism severity index (PESI) 413–414, **413**
 pulmonary hypertension 92, 414
 pulmonary infarction 412
 purine analogues 165
 purinergic receptors (P2Y1 and P2Y2) 432–434, 433
 purpura 57, 215, 356, 356, **357**, 358, 362, 368, 368, 392, 462
 pyelonephritis, multiple myeloma 294
 pyridoxal-6-phosphate 40
 pyridoxal phosphate (vitamin B₆) 17
 pyrimethamine 54
 pyrimidine analogues 165
 pyruvate kinase deficiency 73–74
 5q- syndrome (MDS with isolated del(5q)) 213, 215, 217
 quinacrine (Q-banding) 147
 quinidine 76, 77, 362
 quinine 362
 radiation, diseases due to 141, 172, 314
 radiography 92, 93, 161, 162, 225, 248, 291, 292, 293
 see also chest X-ray
 radiotherapy 243, 251, 253, 254, 298
 Rai staging system 240, **240**, 241
 RANKL (receptor activator of NFκB ligand) 290, 299
 Rapoport–Luebering shunt 18, 19
 RARα protein 173
 rasburicase 158, 159
 rash(es) 128, 328, 359
RAS oncogenes, point mutations 149
 ravulizumab, in PNH 317
 Rb (retinoblastoma) tumour suppressor gene 8
 R-CHOP regimen 271–272, 275, 279, 280
 R-DHAP regimen, mantle cell lymphoma 279
 recombinase activating genes (RAGs) 122, 143
 recombinase enzymes 122
 red blood cells (RBCs) 3, 12, **12**, 13, 14, 14, 17–20, 17, 19, 20, **21**, 24–26, 28, 35, 35, 59, 66–74, 66, **67**, 71, 77, 77, 132, 293, 340, 397, 397, **440**, 440, 441, 448, 452–455, 457, 457–458, 458, 471
 red cell aplasia 317–318, **317**, 318, 319, 443, 469
 red cell concentrate 452, 462, 463
 see also blood transfusion
 red cell distribution width (RDW) 60
 reduced-intensity conditioning (RIC) regimens 324
 Reed–Sternberg cell 152, 247, 248, 249
 refractory anaemia with ring sideroblasts 40
 renal failure **289**, 290, 294, 441–442, **441**, 441
 renal impairment 94, 298, 406, 428
 renal vein thrombosis 409
 reproductive issues, haematological disease treatment 158–159
 reteplase 435
 reticulin network, bone marrow 205, 206
 reticulocyte(s) 14, 14, 25, 70, 70, 132
 reticulocyte counts **21**, 22–25, **23**, 35, 60, 468, 469, 470
 reticuloendothelial (RE) system 66, 66, 122
 retina 21, 22, 115, 300, 300
 retinoid X receptor protein (RXR) 173
 retinopathy, proliferative 92, 95
 retroperitoneal nodes, Hodgkin lymphoma 247
 retroviruses, transfusion-transmitted 456, **456**
 revumenib **164**
 R-factor (R-protein, haptocorin) 51, 53
 Rh antibodies 76, 453, 455, 471, 472
 see also anti-D immunoglobulin
 Rh blood group/system 76, **454**, 455, **455**, 455, 458, 459, 471–473, **472**
 rheumatoid arthritis (RA) 440–441, 441
 ribosomal RNA (rRNA) 14, 318
 R-ICE regimen, large B-cell lymphoma 272
 Richter transformation 238, 241, 243
 ring sideroblasts 39, 212, 215, 216, 313
 ristocetin 379
 ristocetin-induced platelet aggregation (RIPA) 380–381
 rituximab 75, 76, 110, 166, 230, 241, 242, 271–272, 277, 281, 317, 361
 rivaroxaban 418, 423, 427, **427**, 428, **429**, 435
 RNA 14, 25, 29, 81, 212, 318
 Romanowsky stain 41
 romiplostim 218, 361
 Rosai–Dorfman disease 113
 ROTEM® (thromboelastometry) 353+
 rouleaux formation 293, 441, 448
 roxadustat 16
RPS14 gene deletion 213
 rubella 443
RUNX1 gene mutations 141, 151, 314
 RUNX1 protein 5, 227
 Russell viper venom test 407
 ruxolitinib 108, 166, 202, 206
 S-adenosyl homocysteine 58
 sarcoma 113, 172, 207
 SARS-CoV-2 *see* COVID-19 infection
 schistosomiasis 35, 37, 134, 447
 SCU-PA 435
 scurvy 367, 368
SEC23B gene 318
 secondary lymphoid organs 125
 'second genetic hit', in ALL 223
 selectins 7, 8
 self-renewal, stem cells 3, 4, 5
 semen storage 251
 senile purpura 367, 368
 sepsis/septicaemia 349, 390, 444
 serine protease **345**, 348, 349, 371
 serine protease inhibitor (SERPIN) **345**, 348, 378, 403, 419
 serology, blood group 457, 457–458, 458
 serpin **345**, 348, 349
 serpin PC 378
 serum amyloid A protein (SAA) 304, 307, 449
 serum amyloid P (SAP) 303, 304, 305
 serum proteins 122
 severe combined immunodeficiency (SCID) 129
 Sézary syndrome 282–283, 284
SF3B1 gene mutation 39, 40, 149, **211**, 212, 220, 220, 239–240
 shock 413, 460
 short-term haemopoietic stem cells 2

- Shwachman–Diamond syndrome (SDS) 313, 317–318, 318
- sickle cell(s) 24, 91, 91
- sickle cell disease (anaemia) 24, 82, 88, 90–97, **91**, 92–94, 97, 406
- sickle cell trait 88, 91, 96
- sickle chest syndrome, acute 91–92
- sickle haemoglobin (Hb S) *see* haemoglobin S (Hb S)
- sideroblastic anaemia 39–40, **39**, **40**
- siderotic granules, red cells 24, 25, 36, 132, 132, 135
- signal transduction 6–7, 144
- signal transduction inhibitors **164**, **178**
- sinusoidal obstruction syndrome (SOS) 333
- sirolimus 325
- skin necrosis, warfarin-induced 424
- skull, 'punched-out' lesions, myeloma 293
- small lymphocytic lymphoma (SLL) 237, 260, **266**, 282
- see also* chronic lymphocytic leukaemia (CLL)
- 'smear' cells 238
- smouldering myeloma **289**, 290, 294
- 'smudge' cells 238, 238
- sodium citrate 350
- solid organ transplants 334
- solitary plasmacytoma 298
- somatic hypermutation 127, 240
- Southeast Asian ovalocytosis **69**, 70, 71
- SOX11, mantle cell lymphoma 279
- spectrin (α and β) 20, 20, **69**, 341
- sperm storage 158
- spherocytes 69, 70, 70
- sphingomyelin 115
- sphingomyelinase deficiency 115
- spina bifida 58
- spinal cord, subacute combined degeneration 57–58, 58
- splanchnic venous thrombosis 200, 406, 428, 435
- spleen 2, 92, 117, 118, 129, 131–137, 132, 133, **135**, **136**, 264
- splenectomy 70–71, 75, 88–89, 135–136, **136**, 206, 361, 406
- splenic B-cell lymphoma/leukaemia 243, 244
- splenic B-cell lymphoma with prominent nucleoli (SBLPN) **237**, **243**
- splenic lymphoma with villous lymphocytes 244
- splenic marginal zone lymphoma 244, 264, 280
- splenic sequestration, sickle cell disease 92
- splenomegaly 86, 92–93, 113, 128, 133, 134, **135**, 186, 199, 199, 204, 205, 205, 206, 238, 266, 362, 363, 440, 441
- spoon nails (koilonychia) 22, 34
- 'spur' cells (acanthocytes) 24, 442
- Staphylococcus epidermidis* 160, 161
- stasis, thrombosis pathophysiological mechanism 400
- STAT3 gene mutations 244
- STAT family 6
- statins 435
- stem cell(s) 4, 104, 321
- stem cell factor (SCF) 4, 6, 7
- stem cell transplantation (SCT) 76, 103–104, 157, 177–178, 177, 192, 218, 312, 315–317, 320–336, 322, 323, **323**, 324, 327, **330**, 330–332, 331, 332, 335, 366, 443
- stercobilin 66
- stercobilinogen 66
- sterility 58, 257
- steroid purpura 368
- stomach carcinoma 406, 438, 439, 440
- tomatocytes 24
- α -storage pool disease (α -SPD) 364, 364
- δ -storage pool disease (δ -SPD) 364
- Streptococcus pneumoniae* 136
- streptokinase 434, 435
- stroke 92, 435
- stroke volume, increased in anaemia 21
- stromal cells, bone marrow 4, 4, 5–6, **6**, 211, 290
- stromal-derived factor 1 (SDF-1) 4
- subacute combined degeneration of the cord 57–58, 58
- subclavian vein, thrombosis 409
- succinyl CoA 17, 53, 53
- sulphaemoglobinaemia 18
- superficial venous thrombosis 406, 431
- superior vena cava obstruction 409
- superoxide 105
- surgery 95, 405, 426, 428–429
- sutimlimab 76
- syphilis **456**, 457
- systemic (primary) AL amyloidosis 294, 303, **303**, 304–307, 304, 305, 307
- systemic disease, haematological changes 437–450, **438**, 439, **440**, 440, **441**, 441
- systemic lupus erythematosus (SLE) 74, 440
- tachycardia, in anaemia 21
- tacrolimus 325
- taliglucerase 113
- T-ALL *see under* acute lymphoblastic leukaemia (ALL)
- target cell 24, 35, 35, 442
- targeted drugs 166, 179, 233–234, 254, 255
- TBX21 284
- T-cell acute lymphoblastic leukaemia *see* acute lymphoblastic leukaemia (ALL)
- T-cell depletion (TCD), GVHD prevention 325, 333
- T-cell immunodeficiency, after stem cell transplantation 325
- T-cell lymphoblastic lymphoma 260
- T-cell lymphoma 260, 260, 282–285, 283
- T-cell neoplasms 122, **261**
- see also specific neoplasms (as per table 261)*
- T-cell prolymphocytic leukaemia (T-PLL) 244
- T-cell receptor (TCR) 119, 119, 122, 123, 125, 149, 226
- TdT (terminal deoxynucleotidyl transferase) 122, 169, 226
- 'tear-drop' cells (poikilocyte) 24, 205, 206
- TEG* (thromboelastography) 353
- telangiectasia 367–368
- telomerase 148
- telomere(s) 3, 145, 148, 148, 312, 313
- temporal arteritis 441
- tenase 345
- tenecteplase 435
- TERC gene mutation 312
- terminal deoxynucleotidyl transferase (TdT) 122, 169, 226
- TERT gene mutation 312
- TET1 gene 9
- TET2 gene 150, 197, 212, 212, 220
- tetrahydrofolate 53, 53, 54, 404
- thalassaemia 28, 28, **39**, 41, 81, **82**, 82, 83–90, **83**, **84**, **90**, 97
- α -thalassaemia *see* α -thalassaemia
- β -thalassaemia *see* β -thalassaemia
- transfusion-dependent *see* β -thalassaemia major
- α -thalassaemia 82, **83**, 83–84, **84**, 84, 85, 88, 90
- β -thalassaemia 82, **83**, 84–90, **84**
- β -thalassaemia intermedia (β^+) 45, 82, **83**, **84**, 90
- β -thalassaemia major (β^0) 45, 46, 47, **48**, 48–49, 67, **82**, **83**, 84–90, 85–88
- β -thalassaemia trait (β -thalassaemia minor) 82, **83**, 84, 89–90
- $\delta\beta$ -thalassaemia **84**, **90**
- thalidomide 166, 297
- thiamine-responsive anaemia 40
- thienopyridines 433
- thrombectomy 435
- thrombi 394–397, 400, 432, 434
- thrombin (factor IIa) 345–348, 346, 347, 350–351, 353, 376–377, 383, 390, 418, 419, 419, 420, 422, 432
- thrombin activatable fibrinolysis inhibitor (TAFI) **345**, 349, 349
- thrombin time (TT) 351, **352**, 428
- thrombocytopenia 77, 142, 157, 172, 214, 217, 218, 238, 266, 356, 356, 358–367, **358**, 362, **363**, 387, 391, 393–397, 394, 430, 439, 440, 442, 443, **444**, 445, 446, 467–468, 467, 471
- immune (idiopathic) *see* immune thrombocytopenic purpura (ITP)
- thrombocytopenic microangiopathic haemolytic anaemia 77, **358**, 363
- thromboelastography (TEG) 353
- thromboelastometry (ROTEM) 353
- thrombolysis 430, 435
- thrombolytic (fibrinolytic) therapy 430, 434–435, **436**
- thrombomimetics, myelodysplastic syndromes 218
- thrombomodulin **345**, 348, 349
- thrombophilia 400, 402–404, 406–408
- thromboplastin reagent 351
- thrombopoiesis 2, 3
- see also* platelet(s), formation
- thrombopoietin (TPO) 5–6, 340
- thrombopoietin receptor (TPO-R) 340, 361, 366
- thrombosis 136, 200, 203, 206, 376, 377, 390–393, 390, 391, 394, 400–415, 417–436, 438–440, **441**, 468
- arterial *see* arterial thrombosis
- venous *see* venous thromboembolism (VTE); venous thrombosis
- thrombotic microangiopathies (TMA) 77, **358**, 363, 395–398, **395**
- HUS *see* haemolytic uraemic syndrome (HUS)
- TTP *see* thrombotic thrombocytopenic purpura (TTP)
- thrombotic thrombocytopenic purpura (TTP) 77, **395**, 395–397, 396, 397, 443
- thromboxane A2 (TXA2) 339, 344, 344, 432, 433
- thromboxane synthase 344
- thymidine monophosphate (dTMP) 53
- thymus 117, 118
- ticagrelor 432–433, 434
- tick-borne illnesses 77
- tinzaparin **421**, 432
- tirofiban 433, 434
- tissue factor (TF) 345, 346, 346, 351, 390, 393, 406
- tissue factor pathway inhibitor (TFPI) 345, **345**, 348, 348, 377, 378
- tissue plasminogen activator (tPA) **345**, 349, 349, 376, 430, 434–435
- tissue thromboplastin 351
- T lymphocytes (T cells) 3, 3, 12, **118**, 119–121, 120, 123, 125, 125, 128, 128, 129, 157, 262, 325–327, 334, 360
- antigen receptor *see* T-cell receptor (TCR)
- CAR-T cells *see* chimeric antigen receptor T cells (CAR-T)
- cytotoxic T cells *see* cytotoxic T cells (CD8⁺)
- receptors *see* T-cell receptor (TCR)
- TMPSR6 30

- tongue ulceration 110
 topoisomerases 141, 178, **178**
 total body irradiation (TBI) 323–324
 total iron-binding capacity (TIBC) **21**, 35, 36, 41
 toxoplasmosis 447
TP53 gene 9, 239
TP53 gene mutation 141, 144, 149, 152, 171, **211**,
 212, 240, 241, 243, 281, 294
 TPO *see* thrombopoietin (TPO)
 trabecular arteries 132, 132
 tranexamic acid 158, 366, 376, 376, 383, 386, 392
 transcobalamin (TC) 53
 transcobalamin I (haptocorrin) 51, 53
 transcobalamin II 53
 transcranial Doppler ultrasonography
 (TCD) 92, 93
 transcription factors 5, 16, 340
 transferrin 28, 29, 30, 31, 35, 36, 43
 transferrin receptor 1 (TFR1) 28, 29, 30, 31
 transferrin receptor 2 (TFR2) 30, 31, 45
 transfusion(s) *see* blood transfusion; platelet
 transfusions
 transfusional iron overload **43**, 45–49, **46**, 46, 47,
 48, 86, 462
 transfusion associated circulatory overload
 (TACO) 157
 transfusion reactions *see* blood transfusion
 transfusion related acute lung injury (TRALI) 461,
 461
 transfusion siderosis (iron overload) **43**
 transient abnormal myelopoiesis (TAM) 172
 transjugular intrahepatic porto-systemic shunt
 (TIPS) 430
 transplantation, stem cell *see* stem cell transplantation
 (SCT)
 transthyretin **303**, 304, 308
 trauma 392
 trauma-induced coagulopathy (TIC) 392
 trephine biopsy 23, 24, **25**, 25, 205, 206, 239, 239,
 264, 314, 438, 439
 trimethoprim 54
 trisodium citrate solution 350
 tropical splenomegaly syndrome 134–135, 447
 trypanosomiasis 447–448, 448, 457
 TTP *see* thrombotic thrombocytopenic
 purpura (TTP)
 tuberculosis 443
 tumour like lesions with B-cell predominance 285
 tumour lysis syndrome (TLS) 158, **158**, 159, 241
 tumour necrosis factor (TNF) 6, 9, 9, 103, 125
 tumour-suppressor genes 8, 144, 144
TP53 see TP53 gene
 twins, acute lymphoblastic leukaemia in 223, 223
 tyrosine kinase(s) 144, 195, 208
 tyrosine kinase inhibitors (TKI) 144, 186, 188,
 189–190, 190, 227, 230, 233

UBA1 gene mutation 107–108
 UFH *see* unfractionated heparin (UFH)

 UKALL 2003 trial 229
 ulceration 92, 93, 95, 109–110, 110
 ultrasound 411, 411
 Doppler *see* Doppler ultrasound
 umbilical cord blood 321, 468
UNC13D gene mutation 112
 unfractionated heparin (UFH) 418, 419–420, 419,
420, **421**
 unsaturated serum iron-binding capacity (UIBC) 36
 uraemia **366**
 urine 66, 68, 69
 urobilin (urochrome) 66, 67
 urobilinogen 66, 67
 urokinase 434
 urokinase plasminogen activator (uPA) **345**,
 349, 349

 vaccination 94, 136, **137**, 161, 243, 325, 394
 vaccine-induced immune thrombotic thrombocyto-
 penia (VITT) 394, 445
 vadadustat 16
 variant allele frequency (VAF) 219
 varicella zoster virus (VZV) 161, 331, 332
 vascular bleeding disorders 356, 367, 367–368
 vasoconstriction 338, 338, 339, 412
 vaso-occlusive crises, sickle-cell disease 91–92,
 94–95
 vasopressin 2 receptor, agonist 375
 veins, lower limbs 408, 409
 velaglucerase 113
 venesection 45, 200
 venetoclax 9, **164**, 179, 182, 241, 242, 242
 Venofer **38**
 veno-occlusive disease (VOD) of liver 333
 venous sinuses, spleen 132, 132
 venous stasis 404
 venous thrombi 400
 venous thromboembolism (VTE) 76, 400–408,
401, **402**, 405, 414, 418–432, **431**, 435,
 439–440, 468
see also deep vein thrombosis (DVT); pulmonary
 embolism (PE); venous thrombosis
 venous thrombosis 94, 316, 394, 400–414, **401**,
 409, **410**, 430, 431, 438–440
 ventilation-perfusion mismatch 412
 ventilation perfusion (VQ) scintigraphy 413
 vertebral collapse 290, 291
 VEXAS syndrome 107–108
 vinblastine **164**
 vinca alkaloids **164**, 166
 vincristine **164**, 166
 viral infections 141–142, 161, 262, **263**, 331,
 331–332, 443–446, 462
 Virchow's triad 400
 visceral leishmaniasis 447
 viscoelastic tests (VET) 353
 vitamin B₆ (pyridoxal phosphate) 17
 vitamin B9 *see* folate
 vitamin B₁₂ **21**, 51, 51, **52**, 52, 53, 53, 63

 vitamin B₁₂ deficiency 35, **51**, 51–59, 54, **56**, **57**,
 61–63, **61**, **62**, 438, 446, 467
 vitamin B₁₂ neuropathy 57–58, 58, 61
 vitamin C deficiency 367, 368
 vitamin D, osteopenia in thalassaemia major 87–88
 vitamin K 387–389, 422, 423, 426
 vitamin K antagonists (VKA) 418, **420**, 422–426
see also warfarin
 vitamin K deficiency 387–389, **388**
 vitamin K deficiency bleeding (VKDB) 388–389
 vitamin K-dependent (VKD) proteins 387, 422
 vitamin K epoxide reductase (VKOR) 422, 423
 vitiligo **56**
 von Hippel-Lindau (vHL) protein 15, 15
 von Willebrand disease (VWD) 365, 379–382, **381**,
382
 von Willebrand factor (VWF) 342, 343, 365,
 379–382, 380, **381**, 393, 395, 396, 400, 406
 von Willebrand syndrome, acquired (AVWS) **386**, 387
 vorapaxar 433, 434
 voxelotor 95
 VRd therapy, multiple myeloma 296, 297

 Waldenström macroglobulinaemia (WM) **147**,
 280–281, 290, 300, 406
 Waldeyer's ring, non-Hodgkin lymphoma 265–266
 wall shear rates, blood vessels 400
 Warburg effect 250
 warfarin 157, 415, 418, 422–426, 423,
425–427, 430
 warm autoimmune haemolytic anaemia 74, 74,
 75–76, 75
 Weibel–Palade bodies (WPBs) 367, 375, 379, 396
 weight loss 159, 247, 265
 Wells score, modified 409–410, **410**, 410
 West Nile virus 457
 white blood cell(s) (WBCs) 12, 99–130, 100, **440**,
444, 461, **469**
 lymphocytes *see* lymphocyte(s)
 phagocytes *see* phagocyte(s)
see also specific cell types
 white blood cell (WBCs) count **12**, **21**, 22, **100**, **469**
 increased *see* leucocytosis
 Wilson disease 442
 Wiskott–Aldrich syndrome (WAS) 364
 World Health Organization (WHO) 243, 356–357,
358, 452

 xanthine oxidase 158, 159
 X-linked agammaglobulinaemia 129
 XTEN protein 374

 yeasts, infections 161–162
 yolk sac 2

 zanabrutinib 166, 241
 Zieve syndrome 442, 443
 Zika virus 457
 zymogens 344